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CHAPTER I 
INTRODUCTION 
lA. Review of the Related Literature 
IA-1. Division of Immunological Responsiveness 
The first evidence for a division of immunological 
responsiveness came from the work of Glick and Chang (1) 
when they accidently discovered that the bursa of Fabricius, 
a lymphoepithelial organ found exclusively in bir~(2), was 
important in antibody production. In 1962, Miller (3) 
discovered that neonatal thymectomy in virus-induced leukemic 
mice caused a severe depletion of -lymphocytes and a serious 
impairment of the immune response to both injected cellular 
antigens and skin grafts. Warner et ~· (4) was the first to 
demonstrate a clear division of immunological function. He 
proposed that the bursa of Fabricius produced cells which 
differentiated into antibody-producing clones, whereas the 
thymus gave rise to cells responsible for homograft rejection. 
Roitt et ~· (5) in 1969 coined the terms 11 T-lymphocytes or 
thymic-dependent lymphocytes .. , and 118-lymphocytes or bursa-
equivalent lymphocytes ... Since then, T-lymphocytes have 
been shown to be involved in cell mediated responses, such as 
homograft rejections; whereas B-lymphocytes are involved in 
1 
humoral responses (antibody production). 
With the advent of new laboratory techniques in the 
1970's, it became possible to separate T-lymphocytes from 
8-lymphocytes ~n the basis of physical and chemical 
differences (6-10). Table 1 contains a list of differences 
found between T- and 8-lymphocytes.in mice. 
IA-2. Subpopulations ofT-lymphocytes 
T-lymphocytes or T-cells display an extraordinary 
degree of functional heterogeneity. They have been shown 
to generate cytotoxic responses to alloantigens (11-13), 
display helper (13,14) and suppressor (15-20) effects on 
cell-mediated responses, and they help .B cells produce 
antibody to thymus-dependent antigens (21-23). As a result 
of this broad specificity, various groups investigated the 
possibility that more than one type ofT-cell existed. 
The early work seemed to suggest that T-cells were 
a homogenous, multipotent population. Studies in which 
T-lymphocytes were exposed to various doses of mitogenic 
substances (e.g. concanavalin A and phytohemagglutinin 
-M or -P) showed that the T-cell response elicited was dose 
dependent. Rich and Pierce (22-24) have shown that the 
addition of submitogenic amounts of concanavalin A (con A) 
or phytohemagglutin in (PHA) elicits an "enhancing or 
helper effect", whereas mitogenic amounts of either mitogen 
2 
10 
TABLE 1 
3 
Comparison ofMouse BandT Lymphocytes 
Properties 
Differentiation 
Ag-binding receptors 
on the cell surface 
Cell surface antigens: 
Thetaaa 
TLb 
Lye 
pcd 
H-2 Transplantation 
antigense 
Approximate frequency 
(%) in: 
B Cells 
Bursa of Fabricius 
(in birds) or 
lymphoid organ 
equivalent in mammals 
a 
Abundant Ig.(s) 
(restricted to one 
isotype, one allotype, 
and one idiotype per 
cell) • 
+ (plasma cells) 
+ 
Blood 15 
Lymph (thoracic duct) 10 
Lymph node 15 
Spleen 35 
Bone Marrow Abundant 
Thymus Rare 
Functions 
Yes (large lymphocytes 
and plasma cells 
No 
Secretion of Anti-
body molecules 
Helper function 
(reacts with 
"carrier" moities 
of the immunogen 
Effector cell for No 
cell-mediated immunity 
immunity 
T Cells 
Thymus 
Nature of specific 
receptors is 
uncertain. Ig(s) 
are sparse. 
+ 
+ 
+ 
+ 
85 
90 
85 
65 
Few 
Abundant 
No 
Yes 
Yes 
Distribution in lymph 
nodes and spleen: 
Clustered in follicles In interfollic-
around germinal centers ular areas 
continued on following page 
Properties 
Susceptibility to 
inactivation by: 
X-irradiation 
Corticosteroids 
Antilymphocyte 
serum(ALS) 
a 
(continuation) 
++-I+ 
+t-
+ 
B Cells T Cells 
+ 
+ 
-H-+t 
Ig(s) is an abbreviation for immunoglobulins 
a a 
b 
c 
Theta occurs at high levels in the thymus and brain. Two 
allotypes are known: theta-AKR (in AKR and a few other 
inbred mouse strains), and theta-C3H (in C3H, BALB/c, 
and most other mouse strains). 
TL is present on normal thymus cells of only some mouse 
strains (TL+), but is present on leukemic lymphocytes 
of TL+ and TL- strains. 
4 
Ly is present on thymus cells and circulating lymphocytes, 
but absent from all nonlymphoid cells. There are two 
loci: Ly-A and a second one with linked Ly-B and Ly-C; 
two alleles are known at each. 
d 
PC is present on plasma cells(including myeloma cells). 
e 
H-2 histocompatibility Ags. BandT cells also differ 
in ability to absorb Igs: B cells, but not T cells, bind 
Ag-Ab complement (C) complexes through surface sites that 
are specific for activated third component of C (C3). 
Other sites on B cells bind aggregated Igs (cross-linked, 
for instance by Ag), probably through specific reaction 
with the Fe domains of the aggregated molecules. 
results in a "suppressive effect". Thus, they reasoned the 
same population ofT-cells were capable of performing both 
functions, by responding differentially to different 
concentrations ~f con A. However, it has subsequently been 
shown that "helper T-cells" and "suppressor T-cells" are 
equally activated by con A (25); and that the helper response 
is masked by the suppressive effect (25). 
Evidence that distinct subsets ofT-lymphocytes exist 
come from studies which probe differences in the cell surface 
(13,26-44), sensitivity to radiation (38,45-49) and chemical 
substances (38,50-52), and their distribution in different 
animal tissues (37). 
Peripheral T-cells in mice can be. subclassified into 
three types ofT-cells based on the expression of gentically 
controlled surface components of cells undergoing thymus-
dependent differentiation (13,26,27). These surface components 
are referred to as Ly-1, Ly-2, and Ly-3. Each Ly system 
comprises a genetic locus, Ly-1 on chromosome 19, Ly-2 and 
Ly-3 found closely linked on chromosome 6, and each with two 
alternate alleles. Approximately fifty percent of the 
peripheral T-cells express the phenotype Ly 1,2,3, thirty-
three percent the phenotype Ly-1, and five to ten percent the 
phenotype Ly-2,3. Functional studies indicate Ly-1 T-cells 
elicit helper response, while Ly-2,3 elicits both suppressor 
and cytotoxic responses (25,28). Recently it has been shown 
5 
that suppressor T-cells can be differentiated from cytotoxic 
T-cells by the presence of an additional surface component, 
an I-J antigen (29), coded for the I-J subregion of the !-
region of the major histocompatibility complex in mice (30-32). 
The I region of the major histocompatibility complex or H-2 
in mouse (HLA in humans) controls surface antigen which 
stimulate the mixed lymphocyte reactions (MLR), a proliferative 
response ofT-cells in culture to allogenic lymphocytes, and 
graft-versus-host reactions (32). Figure 1 (30) depicits the 
genetic map of the H-2 complex. 
Recently, a new technique of raising monoclonal 
antibodies reactive to a specific cell surface determinants 
has been applied to characterizing human T-cell subclasses. 
A series of the monoclonal antibodies (T1-T10) have been 
developed which are reactive with thymocyte and peripheral 
T lymphocyte cell surface antigens. T-cells carrying the cell 
surface antigens (T1+,T3+,T4+) have been shown to have an 
enhancing (helper) effect in T-cell-T-cell, T-cell-s-cell, 
and macrophage interactions (33,34); whereas cells of the 
+ + + phenotype T1 ,T3 ,T5 have been shown to be cytotoxic (34,35) 
and suppressive (34,35). 
Thus, it appears that the T5+ (T1+,T3+,T5+) T-cell is 
analogous to + + + + + the Ly-~3 T-cells, and the T4 (T1 ,T3 ,T4 ) 
T-cell is analogous to the Ly-1+ found in mice. Therefore, 
like other cell surface molecules (e.g. immunoglobulins, 
6 
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(See Benacerraf) 
Figure 1. Genetic Map of the Major Histocompatibility Complex 
in Mouse (H-2 Complex) 
The H-2 Complex found on mouse chromosome 17 
consists of 5 regions: K,I,S,G, and D. The K and D 
regions contain the H-2K and H-2D marker loci which 
determine cell membrane antigens expressed on almost 
all tissues. The K and D gene products function as 
the major histocompatibility a~tigens. They can 
stimulate cytolytic responses by T-cells and antibody 
responses by B lymphocytes. The S region contains 
the Ss locus which controls components of the 
complement system. The G region contains the H-2G 
locus which controls an erythrocyte alloantigen which 
has not been associated with any biological function. 
The I region is divided into 5 subregions: I-A, I-B, 
I-C, I-E, and I-J. Ir genes which control the ability 
to develop specific immune responses to thymus-depen-
dent antigens are found in the I region. In addition, 
a new class of alloantigens, Ia antigens are coded for 
by the I region. Ia antigens are selectively expressed 
on B lymphocytes and macrophages. 
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and the major histocompatibility complex encoded ant]gens}, the 
antigens defining the phenotypes of inducer and suppressor/cytotoxic 
populations have been conserved, at least in mouse, rat, and man, 
and probably throughout the entire mammalian family. 
Subpopulations of T-cells can also be differentiated on the 
basis of their Fe (36} receptors of immunoglobulins (37}. Four 
types ofT-cells have been identified: T~-cells contain an Fe 
receptor on its cell surface for IgM; Ty-cells a Fe receptor for 
IgG; Ta-cells a Fe receptor for IgA, and T£-cells a receptor IgE. 
These cells are identified and purified by a resulting technique 
using Ox RBC-Ig~ for T~-cells, Ox RBC-IgG forTy-cell~, Ox RBC-
TNP-IgA for Ta-cells, and Ox RBC-IgE for TG-cells (38,39}. It 
should be mentioned that these receptors ·are also present on 
B-cells (37}. Studies with different mitogens have shown T~-cells 
function as helper cells, while Ty-cells function as suppressor 
cells (38-42}. The precise roles of Ta-cells and T£-cells as of 
yet remain to be elucidated; however, T -cells may regulate the 
specific IgA response of B lymphocytes (37,43}. 
T lymphocytes may also be differentiated on the basis 
of receptors for histamine (38}. When purified T lymphocytes 
from peripheral blood was passed over a histamine-coated 
sepharose column (44}, approximately fifty-percent ofT -cells 
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were retained by the column and all the T~-cells passed 
through the column. Thus, it appears two populations of 
Ty-cells (Histamine + and histamine-) exist; and T~­
cells lack histamine receptors. 
T lymphocytes also show differentiated sensitivities 
to radioactivity (38,45-.49), corticosteroids (38,50), 
thymic humoral factor (51), and their responsiveness to 
the mitogens phytohemagglutinin and concanavalin A (52). 
Ty (Ly-2,3+ in mouse) suppressor/cytotoxic cells have been 
shown to be sensitive to low dose (500-1000 rads) 
irradiation~ vitro, while T~ (Ly-1+ in mouse) helper cells 
are resistant to such dosages (49). Segal et ~· (50) have 
shown that pretreatment of mice with hydrocortisone caused 
an inhibition ofT-cell function in humoral immunity, while 
enhancing the graft-versus-host reactivity. Thus, it 
appears that helper cells are sensitive to corticosteroids, 
while cytotoxic activity is enhanced. On the other hand, 
Fauci et ~· (53) has shown that hydrocortisone enhances 
the generation of antibody-secreting cells~ vitro; 
however it is believed that the enhancement was the result 
of the inhibition of suppressor cells. 
Finally, Knapp and Posch (54) found non-activated 
suppressor T-cells appear to be sensitive to hydrocortisone, 
whereas activated suppressor cells seem not to be. In 
addition, they showed that hydrocortisone could enhance or 
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diminish suppressor cell activity depending on the concentration 
used and the time at which the hydrocortisone was added. 
Table 2 (37) summarizes some of the differences between helper 
(T~)T-cells and suppressor/cytotoxic (Ty)T-cells. 
While the evidence supports the existence of subclasses 
ofT-cells, the question arises as to whether the subclasses 
exist prior to activation by antigen or mitogen. Cantor and 
+ + Boyse (26) found that mouse T-cell subclasses Ly-1 and Ly-2,3 
separated prior to antigenic stimulation, express exclusively 
helper or cytotoxic function. Jandanski and his coworkers (25) 
+ + have shown that while Ly-1 and Ly-2,3 T-cells are equally 
activated by con A to incorporate [3HJ-thymidine, Ly-1+ T-cells 
elicit helper responses, while Ly-2,3+ T-cells elicit suppressor 
responses in the sheep red blood cell-plaque forming cell assay 
(55,56); moreover the same results could be obtained even if 
the two T-cell types were separated prior to con A stimulation. 
Finally, Reinhera and his coworkers (33,35) have shown that 
while T4+- and T5+- cell subpopulations are equally activated 
by mitogenic stimulation to proliferate, only the T5+-cell 
population became suppressive. Therefore, in addition to 
existing as distinct subclasses, the nature of the T-cell 
appears to be established prior to activation by antigens or 
mitogens. 
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TABLE 237 
CHARACTERISTICS OF HUMAN T CELL SUBPOPULATIONS 
Characteristics: 
B-cell differentiation 
T-cell proliferation 
Natural killer activity 
Antibody-dependent 
cytotoxicity · 
Blastogenic responses to 
Phytohemagglutinin 
Concanavalin A 
Allogenic cells 
Mediator production 
Migration Inhibition 
Factor(LMIF) 
Interferon 
Adherence to nylon wool 
or glass 
Electrophoretic mobility 
Locomotor properties 
Ia antigen 
Histamine receptors 
Thymopoietin · 
Sensitivity to 
Corticosteroids 
Irradiation 
Pronase 
Trypsin 
Neuramidase _ 
RNA content 
Morphology 
Cytoplasmic/Nuclear 
ratio 
Golgi body 
Rough endopiasmic 
reticulum 
Cytoplasmiclgranules 
Alpha-nep~thyl __ a.c~~a~e 
esterase. 
Tll.Cells 
ts 
? 
+ 
+ 
+ 
+ 
+ 
High 
+ 
+ 
+ 
+ 
High I 
Low 
Few 
Scanty 
+ Granular 
Ty .Cells 
-ts 
-ts 
+S 
+S 
+ 
+ 
+ 
+S 
tow 
+ 
+S 
t 
+ 
+ 
+ 
Low 
High 
Rich 
Abundant 
+ 
Symbols: S • subpopulation, t = enhancement, ~ = inhibition 
+ • positive, and - = negative 
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IA-3. Suppressor T-cells 
The first information concerning suppressor T lymphocyte 
activity was provided by Gershon and Hondo (58) of Yale in 1970. 
In their paper they described experiments which showed that a 
state of non-responsiveness to a particular antigen could be 
transferred to an animal which had been previously responsive to 
that antigen. In their experiment, lymphocytes from mice made 
tolerant to sheep RBCs were adoptively transferred into mice 
capable of responding to sheep red blood cells (SRBCs). The 
recipient mice were then found to be non-responsive to SRBCs. 
Since then, suppressor T-cells have been shown to play a 
role in a number of humoral (58) and cell-mediated processes 
(16,20,57-63). In addition, suppressor T-cells have been shown 
to be involved in the etiology and pathogenesis of a number of 
disease states such as Hodgkin's disease (64), multiple sclerosis 
(65), systemic lupus erythematosus (66,67), inflammatory bowel 
disease (68), allergies (69), common variable hypogammaglobulinemia 
(70), aging (71), and renal allograft rejection (72,73). 
Experiments with the antimetabolite cyclophosphamide (29), 
show that two types of suppressor T-cells exist. The 11 initiator 11 
suppressor T-cell is sensitive to cyclophosphamide, while the 
11 effector 11 suppressor T-cell is resistant to cyclophosphamide. 
Upon antigen or mitogen stimulation, the initiator suppressor T-
cell is activated to produce a soluble suppressor factor which 
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then activates the effector suppressor T-cell. The effector T-
cell then carries out suppressive actions on T-cell to T-cell 
and T-cell to B-cell interactions. 
IA-4. Mechanism ofT-cell Suppression 
The mechanism by which suppression T-cells inhibit the 
various humoral and cell-mediated responses remains largely 
unknown. However, it appears that the inhibition of cellular 
proliferation may represent a common pathway by which a variety 
of suppressor T-cells regulate both humoral and cell-mediated 
immune responses. It can be demonstrated that suppressor T-
cells induced by either antigenic (57,76) or mitogenic 
stimulation (22) are both capable of suppressing proliferative 
B-cell responses and antibody formation (74). Moreover, 
suppressor T-cell populations have been shown to suppress T-
cell proliferation and the development of cytotoxic T-cells in 
mixed lymphocyte culture (20,63,76,77). 
Another manner in which suppressor T-cells act is by 
interferring with cell to cell interactions between T-cells or 
between macrophages and T-cells. Ferguson et ~· (125) have 
shown that murine spleen cells cultured in the presence of 
heterologous serum suppressed normal spleen cells from 
responding in a cell-mediated cytotoxicity (CMC) assay. In 
addition, suppression was shown to be exerted on some early 
phase of cell-mediated cytotoxicity generation. 
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Besides the mode of suppression, another facet of suppression 
which must be addressed is that of the target ofT-cell suppression. 
In the case of suppression of humoral immune responses, i.e. immune 
phenomena involving the production of specific antibody, the 
immediate target could be a specific helper T-cell, a macrophage, or 
even the B-cell (79,80). 
Tada and his co-workers (74) have presented evidence that 
the immediate target of suppressor T-cells are specific helper 
cells. By transferring lymphoid cells (spleen and thymus) from 
rats immunized against a specific hapter-carrier conjugate (e.g., 
dinitrophenol (DNP)- Ascaris or DNP - Bovine Serum Albumin (BSA)) 
into syngenic rats, i.e. rats inbred until homozygous for all gene 
loci, producing the antibody IgE, they were able to show 
suppression to be dependent on helper T-cells which carried 
specific determinants for the carrier molecule. 
Another possible target of suppressor T-cells is the B-cell. 
Baker (81) was able-to show the inhibitor of antibody responses 
by suppressor T-cells interacting directly with a B-cell membrane 
determinant. Additional evidence which points to the S-cell as 
being the immediate target of suppression comes from the work of 
Pierce and his co-workers (75). They showed that T-cells from 
patients suffering from hypogammaglobinemia suppressed the 
immunoglobulin synthesis by normal B-cells, presumably by acting 
directly on the B-cells or on macrophages. Figure 2 depicts 
three possible models for T-cell regulation of B-cell responses. 
15 
16 
LEGEND 
Figure a. Possible models for T cell regulation of B 
cell responses: (a) The same T cell gives 'on 
and off' signals to B cell, in which 'too much 
help' ,would become inhibitory; (b) two 
differnt types of T cells(helper and suppre-
ssor) give differnt signals to B cell; (c) 
Helper T cell sends 'on' signal to both Bs 
(sensitive B) cell and the suppressor T cell. 
A sufficient number of suppressor T cells 
thus generated would in turn suppress both 
helper T cell and sensitive Bs cell, The 
response of insensitive(T cell-independent) 
Bi cell are not affected. 
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Evidence that the macrophage is the immediate target of 
suppressor T-cell actions comes from the work of Basten et ~· 
{82). Leukocytes made tolerant to human gammaglobulin (HGG) 
were treated with anti-thy serum and complement, or passed through 
an anti-immunoglobulin coated column to obtain purified tolerant 
T-cells. Thy-1 or theta is an antigen found on T-cells in the 
mouse. When the HGG-tolerant T-cells were injected into irradiated 
hosts they failed to inhibit the anti-DNP response. However, when 
the HGG-tolerant T-cells were injected along with a second 
population of cells possessing adherent properties, suppression 
of the anti-DNP response was completely restored. Since it 
appeared that the second cell population was probably not comprised 
ofT-cells, but rather ~cells or macrophages, the tolerant cells 
were passed through a column coated with an irrelevant antibody 
(e.g., anti-sheep red blood cell antibody). Immuno-fluorescent 
staining with anti-immunoglobulin confirmed normal number of 
B-cells were present in effluent. When the cells obtained from 
the effluent were transferred into irradiated hosts, minimal 
suppression of the anti-DNP response occurred. Apparently, the 
column removed the adherent cells, which were most likely 
macrophages. Confirmatory evidence that this was the case was 
obtained by passing tolerant spleen cells through a glass wood 
column which retains macrophages. 
As is the case with humoral responses, various T-cell and 
non-T-cells (e.g., B-cells and macrophages) appear to be targets 
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of cell-mediated suppression. Gershon and co-workers (83) have 
shown that T-cell mediated processes such as graft-versus-host 
rejection (GVHR) were repressed or inhibited by the direct action 
of suppressor T-cells on other T-cells. Several studies of the 
mechanism of suppression of cytotoxic T-cells indicate that 
suppression is mediated by both T-cells and non-T-cells (84-87}. 
Rode et ~· (88) have proposed two mechanisms by which suppressor 
T-cells inhibit cytotoxic lymphocyte activity in humans: The 
first involves the suppressor cell binding to, or in some manner 
preventing helper T-cells from mediating cytotoxic activity. The 
second mechanism suggests that suppressor T-cells abrogate cytotoxic 
T-cell activity by inhibiting precursors of cytotoxic T-cells. 
Kimple and Henney (89) have presented evidence which 
suggests that suppressor T-cells act on macrophages, which in turn 
prevent cytotoxic T-cell activity by preventing cytotoxic T-cell 
precursors from differentiating via DNA-independent mechanisms. 
The final factor to be considered involves the manner in 
which suppressor T-cells transmit their effect; that is, either 
by direct contact with their target or by the elaboration of 
suppressor factors which then suppress the intended target. A 
number of suppressor factors secreted by activated suppressor 
T-cells have been identified (15,74,76,90). 
Tada and his co-workers (74} have isolated two suppressor 
factors. One is a small membrane-sound protein from spleen 
cells which is capable of suppressing IgE-synthesis. The other 
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suppresses the IgG response to Keyhole Limpet Hemocyanin (KLH), a strong 
thymus-dependent antigen often used in hapten-carrier conjugates. 
Benaceraff and his co-workers {76) have identified an antigen-specific 
suppressor T-cell factor which appears to be involved in the genetic 
control of the specific immune response to the polypeptide gly-ala-
tyrosine. 
Suppressive factors which suppress cell-mediated processes have 
also been identified. Zembala et ~· (15) have isolated a T-cell 
suppressor factor which is capable of depressing the passive transfer 
of contact sensitivity of mice to picryl chloride (PCl), which had been 
applied to their skin after pretreatment with picryl sulphonic acid 
(PSA). In contrast to the factor described by Tada and others, this 
factor was released into the media from cultured primed lymph nodes. 
Finally, Truitt and co-workers (87) have identified two different 
suppressor factors. One, MLR-TSF has been shown to suppress lymphocytes 
from undergoing blast formation {proliferation) in mixed leukocyte 
culture reactions. The second, CTL-TSF suppresses the generation of 
cytotoxic lymphocytes in mixed leukocyte cultures. 
While additional work is needed to elucidate the mechanism(s) 
of T-cell suppression, it appears that various cell-mediated and 
humoral mediated responses are regulated by a number of different 
suppressor pathways. In addition to suppressor T-cells, other T-cell 
and non-T-cells have been shown to play an important role in the 
suppression of the many cell-mediated and homoral immune responses. 
IA-5. Role of Suppressor T-cells in Renal Allograft Rejection 
Graft rejection usually follows transplantation of tissues 
between unrelated individuals because of an immune response by the 
recipient towards antigens expressed on cells within the graft (73). 
Graft rejection (acute rejection) is considered to be largely a cell-
mediated immune response (90), although humoral immune responses also 
play a role, and appear to be the main cause of hyperacute rejection 
(91}. Evidence supporting the contention that acute renal allograft 
rejection is a cellular-mediated process comes from studies of 
patients whom were treated with anti-thymus globulin (ATG), a known 
patient inhibitor of cell-mediated immunity (90). 
Because allograft rejection is looked at as largely a cell-
mediated phenomenon, various groups have looked into the role the 
various subclasses ofT-cells play in the processes of rejection. 
The role cytotoxic T-cells play in renal allograft rejection has 
been fairly well characterized (92-94). However, little is known 
about the roles that helper T-cells and suppressor T-cells play (92). 
Evidence that suppressor T-cells are involved in transplant 
tolerance comes from experiments that are essentially extensions 
of the early transfer of tolerance experiments of Argyris (95-96). 
He showed that mice exposed to whole-body irradiation and then 
innoculated with cells from tolerant donors became specifically 
tolerant themselves. Kilshaw and Brent (97) were able to demonstrate 
suppression of the rejection of skin allografts when T-cells were 
adoptively transferred from mice with intact long standing skin 
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grafts to low dose irradiated syngenic recipients, although normal 
cellular immunity was observed in vitro. Numerous other transfer 
experiments (see review 73) have been done; however, the results of 
these experiments to demonstrate suppressor T-lymphocytes in renal 
allograft tolerant hosts by in vitro assays have been contradictory 
and particularly difficult to relate to the in vivo situation. 
Other types of experiments have demonstrated that suppressor 
T-cells are probably involved in suppression of renal allograft 
rejection. Jayavant et ~· (73) was able to show the existence of 
suppressor cells in human renal allograft recipients. They showed 
that there was a significant correlation between a functioning, 
nonrejecting allograft and the allograft recipient•s suppressor cell 
activity. Hendry et ~- (98) showed that while suppressor cells were 
present in the thymus of rats during the first week or so after 
transplantation, they were unable to demonstrate their presence in 
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long-tenm kidney allograft recipients. Liburd and his co-workers 
{99-101) have shown the existence of donor-specific suppressor T-
lymphocytes generated in vivo in renal allografted recipients, capable 
of suppressing the in vitro generation of cytotoxic cells in normal 
responders. Thus, suppressor T lymphocytes appear to be involved 
in the process of allograft tolerance. However, their mechanism 
of action still remains to be elucidated. 
IA-6. Monitoring of Renal Allograft Rejection 
The main problem that renal transplant patients face is 
rejection of the donor graft. In an effort to prevent rejection, 
a number of immunosuppressive drugs (e.g. prednisone and 
azathioprine) have been used. While immunosuppressive therapy 
has enjoyed some success in reversing rejection episodes, the 
therapy remains ineffectual in about 50% of cadaver transplants 
(102). Furthermore, the use of immunosuppressants results in the 
inappropriate suppression of the host's immune response, which 
protects the recipient against infection, and is responsible for 
about 60-70% of recipient deaths post transplant (102). In an 
effort to predict rejection crises and assist in evaluating the 
efficacy in immunosuppression, a number of different approaches 
have been undertaken. 
The initial approach to predicting kidney graft rejection 
depended on monitoring metabolic changes in peripheral blood 
leukocytes. Hersh et Al· (103) showed that DNA synthesis in 
peripheral blood leukocytes increased at the time of rejection. 
Page et ~- (104) found that an increase in DNA synthesis by 
peripheral blood lymphocytes was predictive of a rejection crisis. 
In addition, the measurements of DNA synthesis (lymphocyte 
blastogenesis) allowed for judging the adequacy of immunosuppressive 
therapy for these crises. 
Parker and Mowbray (105) showed the rate of RNA synthesis 
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increased during a rejection episode. In addition,.this increase 
in RNA synthesis was accompanied by a simultaneous increase in 
the number of large, atypical mononuclear cells which appear to 
resemble immature cells of the myeloid series. Furthermore, they 
showed that both the increase in RNA synthesis and the increase 
in large, atypical monocytes occurred 8 to 9 days before rejection 
was clinically evident. 
Another method used to monitor renal allograft rejection 
was measuring the blastogenic response of peripheral blood 
lymphocytes subjected to either mitogenic {e.g. phytohemagglutinin) 
or antigenic {donor or third party lymphocytes) stimulation. When 
phytohemagglutinin {PHA) is used, the assay is sometimes referred 
to as "PHA escape". 
Work by Thomas and his co-workers {106,107) have suggested 
that the measurement of PHA-induced blastogenesis was a useful 
technique for detecting a prerejection state, especially when 
used in conjunction with measurements ofT-cell levels {107). 
On the other hand, Page et ~- {104) demonstrated that 
monitoring lymphocyte responsiveness to phytohemagglutinin was of 
no value in predicting rejection or in evaluating the efficacy 
of immunosuppression. In accordance with these findings, 
Copeland et ~· {108) showed the response of lymphocytes to 
specific and non-specific mitogens proved to be neither useful 
for predicting rejection nor as a guide to the adequacy of 
immunosuppression. Finally, Buckingham et ~- {109) showed 
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that the serial assessment of transplant recipients.using mitogenically-
induced lymphocyte blastogenesis did not reliably predict rejection. 
However, they found that protein synthesis, using the ratio of 16-hour 
PHA-stimulated lymphocytes to non-stimulated lymphocytes, increased 
prior to the onset of rejection. Similar analysis of mitogen-induced 
DNA-directed blastogenesis ratios revealed no significant difference. 
A second approach to the monitoring of renal allograft rejection 
involved measuring T-cell levels. Thomas and his co-workers (106,107) 
found that the most critical determinant of both accelerated and early 
acute rejection was the level and reactivity of circulating thymus-
derived (T) lymphocytes. Using a figure of 360 T-cells/cubic millimeter 
or 20% of the normal circulating T-cell level, Thomas and his co-workers 
(107} found that over 80% of recipients demonstrating acute rejection 
had T-cell levels above 20% of normal. In contrast, a majority of 
patients not experiencing acute rejection in the first posttransplant 
month had T-cell levels below 20% of normal. These differences were 
significant at P less than 0.05. In addition, the mean time of 
appearance of elevated T-cell levels (above 20%) prior to the onset of 
clinically apparent rejection was 5.9 days. Buckingham et 2l· (109) 
also found T-cell levels to be indicative of acute rejection. In 
contrast to the other groups, they found that rejection takes place 
in an environment of decreased numbers ofT- and B-lymphocytes as 
compared with normally observed levels. 
Finally, Kerman and Geis (110,111) found immunologic monitoring 
of a subpopulation of peripheral blood T-cells known as the active 
T-rosette forming cells (active T-RFC) represent an.effective method 
for defining and predicting rejection episodes. In addition, they 
suggested that monitoring active T-RFC levels might be beneficial 
in accessing the effectiveness of daily antithymocyte globulin (ATG) 
dosages, as well as delineating other interventions which alter the 
recipients' peripheral T-cell level. When an allograft recipient 
experienced a clinical rejection episode, a decline in the percent of 
active T-RFC occurred. Therefore, it has been suggested that the 
active T-RFC represents an "immunocompetent" cell (ll2-114), capable 
of recognizing and attacking the allograft; thus, explaining its , 
decline durign a rejection episode. 
Humoral and cellular-mediated immune responses play a decisive 
role in the acceptance or rejection of allogenic grafts (115). In 
clinical transplantation of kidneys, both hyperacute and chronic 
rejection appear to result from circulatory antibodies whereas acute 
rejection episodes appear to be due to the a~tivation of cell-
mediated immune responses (116). Thus, the final approach used to 
monitor kidney post-transplant patients involved tests which measured 
the immunologic responses of the graft recipient to specific antigens 
of the graft donor. 
Cell-mediated lymphocytotoxicity is a measure of recipient's 
effector cells, i.e. cytotoxic T-cells, null cells, or macrophages 
to lyse target cells, i.e. PHA-activated lymphocytes obtained from 
the spleens of cadaver donors or from the peripheral blood of a 
single donor, labeled with chromium-51. Stiller et ~- (116) found 
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cell mediated lymphocytotoxicity (CML) to be highly predictive of 
rejection episodes. They obtained positive CML responses for 41 of the 
45 patients experiencing rejection episodes; whereas only 4 of 29 
patients demonstrated positive CML during periods of clinical quiescence. 
In addition, they showed that the ability of the test to predict a 
rejection episode was independent of when the test was carried out. 
Statistically comparable results were obtained whether the test was 
carried out one day, one week, or two weeks prior to the onset of 
clinical rejection. Thomas and his associates (117) found a high 
correlation between negative CML (specific CML unresponsiveness) and 
graft survival. In addition to enhanced survival, they found that 50% 
of the patients (5 of 10 patients) exhibited a significant suppressive 
effect on third-party to donor cell-mediated lymphocytotoxic responses. 
The role of suppressor cells in the regulation ofT-cell mediated immune 
reactions (e.g. suppressor T-cell inhibition of cytotoxic T-cell 
responses) have been previously reviewed (Sections IA 3-5) and will be 
further discussed in the Results and Discussion Sections. 
Another test which has been used to monitor renal allograft 
rejection is direct lymphocyte mediated cytotoxicity (LMC). Direct 
LMC is an in vitro test of cell-mediated immunity which reflects 
in vivo sensitivity toward a specific antigen. In addition, LMC is a 
thymus-dependent, non-complement-requiring process in which close cell-
to-cell contract is a prerequisite (118). While there appears to be a 
good correlation between CML activity and chronic renal rejection 
(118,119), LMC has proved to be an invaluable prognosticator of acute 
rejection, especially in patients treated with antilymphocyte globulin 
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(ALG)(l07,119,120). 
A third specific anti-donor test which has been used to 
measure both acute and chronic rejection is antibody-dependent cellular 
cytotoxicity (ADCC). Antibody-dependent cellular cytotoxicity is a form 
of lymphocyte-mediated cytotoxicity in which an effector cell kills an 
antibody-coated target cell (e.g. lymphoblast or tumor cell), presumably 
by recognition of the Fe region (121) of the cell-bound antibody through 
an Fe receptor present on the effector lymphocyte (122). The mechanism 
of ADCC is depicted in Figure 3. Unlike CML and LMC where the main 
effector cell is the cytotoxic T-cell, the main effector cell in ADCC 
appears to be a "null" or K lymphocyte (122). 
Thomas and his co-workers (101) found that anti-donor ADCC was 
associated with early acute renal rejection if present pretransplant or 
in the first two post-transplant weeks. On the other hand, ADCC which 
developed after the first two post-transplant weeks was found not to be 
indicative of acute rejection. In an earlier study, Thomas and his 
associates (123) showed that a positive correlation existed between 
chronic renal allograft rejection and ADCC activity. In the study, 
seven out of the seven patients, 1 to 10 years post-transplant, 
exhibiting clinical symptoms, i.e. persistent proteinucia greater 
than 1 gram per 24 hours, of chronic rejection, displayed positive 
ADCC values, whereas, 11 out of the 13 (85%) patients (2 to 11 years 
post-transplant) not showing clinical symptoms of chronic renal 
allograft rejection had negative ADCC values. Recent studies 
(120,124) have also shown that monitoring ADCC activity to have 
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Figure 3: The process of antibody-dependent cell mediated cyto-
toxicity (ADCC) is illustrated. Specific antibody, 
secreted by plasma cells, binds to cell surface antigens 
on the tumor cell. "Null: or K cells possessing Fe 
receptor bind to the Fe portiop of these cell associated 
antibodies, and kill the attached tumor cells. 
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prognostic value for acute allograft rejection. 
The final two methods used to monitor renal allograft rejection 
involved measuring the amount of lymphocyte-dependent antibody {LOA) 
activity or complement-dependent antibody {COA) activity. Thomas and 
his co-workers (119) found a strong correlation between LOA activity 
and chronic, renal rejection. Ninety-three percent of LOA-positive 
patients had a clinical course characteristic of chronic rejection, 
whereas 92% o'f LOA-negative patients demonstrated good rena 1 function, 
i.e. renal function as defined by creatinine, creatinine clearance, 
and urine protein. On the other hand, Stiller et ~· {116) showed 
that there was no statistical difference for LOA activity between 
patients experiencing rejection episodes or patients without rejection 
episodes. 
With regards to the complement-dependent antibody test, 
Stiller et ~ {116) show that there was a clear association between 
COA activity and rejection. Of 15 rejection episodes, COA was positive 
in 12, and on no occasion was COA activity positive during a period of 
quiescence. The various tests are summarized in Table 3. 
lB. Effects of Splenectomy, Pretransplant Transfusion and Anti-
Globulin Administration in Renal Transplantation 
IB-1. Effect of Splenectomy on Renal Allograft Survival 
Splenectomy as an adjunct to kidney transplantation was first 
suggested by Starzl and his co-workers {125,125) as a way of reducing 
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TABLE 3 
Summary of the Various Immune and Metabolic Tests to 
Monitor Acute and Chronic Renal Rejection 
* Name of Test Type of Rejection Monitored 
DNA/ RNA Synthesis Acute 
PHA or Con A Blastogenesis Acute 
T Cell Levels Acute 
Mixed Lymphocyte Culture Acute 
Tnymus-Dependent Rosette-Forming Acute 
Cells 
Ce 11-Medi a ted Lymphocytotoxi city Acute and Chronic 
Lympnocyte-Mediated Cytotoxicity Acute 
Antibody-Dependent Cellular Acute and Chronic 
Cytotoxicity 
Lymphocyte-Dependent Antibody Chronic 
Complement-Dependent Antibody Acute 
* Represents the various tests which are discussed 
in the text. 
the total lymphoid mass, i.e. spleen and thymus, so as to diminish 
allograft rejection. In addition, they suggested that splenectomy 
would also permit the use of larger doses of the immunosuppressant 
azathiopine, a practice which would also contribute to the prevention 
of rejection. 
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Subsequent studies on splenectomy as a therapeutic tool against 
renal allograft rejection have been inconclusive. Veith et ~· (127) 
were unable to demonstrate any beneficial effect of splenectomy in a 
small series of canine and human homotransplants. Bennett et ~- (128) 
reported that pretransplant splenectomy did not decrease the number of 
rejection episodes per month of graft function, and were associated 
with a higher rate of septic, i.e. systemic disease caused by the 
presence of microorganisms or their toxins in the circulatory blood, 
and thromboembolic, i.e. embolism from a clot dislodged from a vein, 
complications. Opelz and Terasaki (129) in a study of 1653 renal 
transplant patients obtained- from 51 transplant centers, were unable 
to demonstrate any beneficial effect of splenectomy. More recently, 
Rai et ~· (130) carried out a retrospective study of 199 patients who 
had received a kidney transplant between January, 1968 and June, 1974. 
They found that there was no significant difference in graft loss 
between patients who had undergone splenectomy, and those which did 
not (control group). In addition they showed that splenectomy did not 
reduce leukopenia, i.e. reduction below 5000 per cubic millimeter in 
the total number of leukocytes in the circulatory blood, so as to 
permit the use of larger doses of azathioprine. Finally, the group 
which had a splenectomy experienced a higher mortality rate, largely 
due to an increased susceptibility to infection. 
While the preceding studies contra-indicate splenectomy as 
34 
a therapeutic adjunct to transplantation, other studies reported 
improved graft survival. Kauffman et ~· (131) found a much lower 
rejection rate in forty recipients splenectomized prior to transplant-
ation than in twenty-three patients splenectomized after transplantation 
or in the thirty-one patients who retained their spleen throughout 
the test. In addition, they found that the white blood cell count 
of patients who had a pretransplant splenectomy was significantly 
higher at day thirty postoperatively, than the white blood cell 
counts of patients who had a splenectomy after transplantation, or 
not at all. Moreover, this increase in white blood cells permited 
the more effective use of immunosuppressive drugs. 
IB-2. Therapeutic Enhneement of Renal Allograft Survival With 
Pretransplant Transfusion 
Prior to the finding of Opelz and Terasaki (132) that the 
administration of blood transfusions to dialysis patients awaiting 
transplantation was associated with improved graft survival, it had been 
the practice of transplant services to minimize transfusion prior to 
transplantation to avoid presensitisation and fromation of cytotoxic 
antibodies. Since then, numerous retrospective studies have confirmed 
that pretransplant transfusion improved renal allograft survival for 
cadaveric kidney recipients (133-137). Finally, the U.S. Registry 
which deals with the results obtained from the majority of American 
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centers estimated in its final report of 1977 that the average effect 
of transfusion on one-year survival of cadaver kidney grafts was 44% 
without compared to approximately 60% with transfusions (138). While a 
majority of the studies on cadaver kidney recipients indicate a positive 
effect for pretransplant transfusions, two groups, Jeffery and his 
co-workers (139,140) and Sengar et ~· (141) failed to demonstrate graft 
prolongation due to pretransplant transfusions. However, their failure 
to demonstrate positive effects on one-year graft survival due to 
pretransplant transfusions could be attributed to the extremely high 
survival rate of the non-transfused recipients (71% for Jeffery's group 
and 75% for Sengar's group). 
A second area which has not been as exhaustively studied as the 
preceding one, is the effect of pretransplant transfusion or graft 
survival in living related recipients. Patients that received kidney 
transplants from living-related donors may, from an immunological point 
of view, be divided into two rather homogenous groups: those that 
received HLA (histocompatibility antigens in humans) - identical grafts, 
and those receiving one halotype (inheritable antigens or genes from 
one parent) mismatched ones. In a study of 191 consecutive living 
related transplant patients, Solheim and co-workers (142) found that 
transfusions enhanced graft survival for transplant patients with one 
HLA halotype - disparabe kidney, whereas transfusions had no effect 
on the survival of HLA-identical transplants. In addition, the 
frequency of first rejection episodes was significantly reduced in 
transfused compared to non-transfused one halotype-mismatched 
transplants, while no influence of blood transfusions was seen 
in patients with HLA-identical transplants. 
Three additional factors which have been investigated 
are the effect of timing, number and the nature of transfusions 
on graft survival. Stiller et ~· (143) observed that transfusion 
given on the day of transplantation were effective in increasing 
graft survival. Hunsicker et ~· (144) found that transfusions 
given on the day of transplantation were statistically as 
effective as transfusion administered prior to transplantation 
(Figure 4). Finally, Freeman et 2.]_. (145) provided data which 
indicated that preoperative transfusions, i.e. blood given during 
the operation, contributed to graft survival. 
Studies on the effect of administ"ering multiple transfusions 
suggested that multiple transfusions enhanced graft survival. 
Hunsicker et ~· (144) showed that maximum graft enhancement at 
three months could be achieved with as few as 3 units of blood. 
Opelz and his co-workers (146) demonstrated that graft survival 
corresponded to the number of blood units transfused, with maximum 
survival rates occurring at greater than 20 units of blood 
transfused. While the majority of studies confirm the enhancing 
effect of multiple blood transfusion on renal allograft survival, 
Van Rood et ~· (147) found no correlation between the number of 
transfusions and ultimate survival. 
The blood administered in transfusions can be of several 
types: Whole blood, red blood cells only, washed cells (leukocyte 
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poor}, plasma, or packed red blood cells (148). Hunsicker et al. 
found there was no significant difference in graft survival between 
patients receiving only frozen erythrocytes and those receiving 
only leukocyte poor packed erythrocytes (77% and 81%, respectively). 
Briggs et ~· (149} obtained results which showed no significant 
difference in graft survival between patients receiving frozen-
thawed red cells or whole blood (29% and 23%, respectively). Opelz 
and Terasaki (149) had earlier demonstrated that frozen blood was 
somewhat less effective than packed cells or whole blood in 
producing a beneficial effect on transplant outcome. 
IB-3. Effect of Anti-Thymocyte Globulin Administration on Renal 
Allograft Rejection 
The most common method currently used to treat acute 
rejection of renal allografts is to temporarily increase the dose 
of corticosteroids. Unfortunately, protocols utilizing oral 
administration of divided doses of steroids are not always 
successful in reversing rejection, and are frequently associated 
with side-effects and long-term complications. In an attempt to 
avoid some of the toxic effects of high-dose corticosteroid 
treatment, many physicians have turned to the intermittent 
intravenous administration of Solu-Medrol (methyl predisolone) 
for reversing rejection. While Solu-Medrol has been reported 
to have been effective in reversing rejection (151,152), 
widespread usage appears to be associated with definite risks, 
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e.g. unexpected cardiac arrhytMlias, infection, and gastrointestinal 
hemorrhage. With this in mind, several transplant groups have 
turned to the use of anti-thymocyte globulin (ATG), either as an 
adjunct or in place of high dose steroids. 
The immunosuppressant ATG represents the globulin fraction 
of antilymphocyte serum (ALS). It is prepared by injecting T, B, 
or mixtures ofT and B-cells from humans into horses, and isolating 
the globulin fraction of the resultant horse anti-serum. 
Early studies on animals showed that antilymphocyte 
globulin (ALG) had a positive immunosuppressive effect in a 
majority of the experiments. The first clinical studies on humans 
were carried out by Starzl and his co-workers (153). Using 
living-related donors with good histocompatibility, they found 
that when ALG was given 5 days before transplantation and continued 
for 4 months, kidney .survival rates improved. In addition, steroid 
doses were cut in half, and azathioprine doses were reduced. On 
withdrawal of ALG from patients who had received kidneys from 
non-related cadaveric donors with poor histocompatibility, 
Starzl et ~· noted a progressive deterioration in the graft. 
Commenting on Starzl 's work, Van Rood (154) noted that ALG permitted 
the reduction of steroids in cases where there was a good match 
for histocompatibility antigens, but could not override the strong 
histocompatibility differences in the group of non-related donors. 
Since then, Starzl and his co-workers (155) have attempted to 
prevent late rejection in homografts with histocompatibility 
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differences by increasing the dosage of ALG, but their efforts have 
been limited by the manifestation of thrombocytopenia, and lymphopenia, 
i.e. decreases in the patient's platelets and lymphocytes, respectively. 
An additional study by Mee and Evans (156) of patients who had received 
a cadaver kidney with at least two major antigens mismatched, showed 
that the patients who had received antilymphocytic serum (ALS) or 
antilymphocyte globulin (ALG) in addition to steroids and azathioprine, 
demonstrated survival rates that were no better than patients receiving 
only steroids and azathioprine. 
Controlled, randomized studies by Shiel et ~· (157) and 
Taylor et ~· (158) showed that recipients of related and cadaver 
kidneys who were treated with ALG had improved kidney and patient 
survival when compared with the non-ALG treated (control) patients. 
Contradictory results have been obtained by Howard et ~· (159). In 
a randomized, double-blind study of renal transplant patients treated 
with ALGor human IgG (control) in conjunction with the standard 
immunosuppressive therapy, they found that the number of patients 
requiring transplant nephrectomy, i.e. removal of kidney(s), and/or 
dialysis, having good late function, or dying did not differ in 
recipients of either living-related or cadaver kidneys; and only 
recipients of cadaver kidneys showed significantly fewer second 
rejection episodes. Similar results were also obtained by Birtch et ~· 
(160) and Turcott et ~· (161 ,162), who were unable to demonstrate any 
significant benefit of either ALGor antithymocyte globulin (ATG) 
administered in the posttransplant period. 
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While the studies on the benefits of ALG and ATG treatment 
have been inconclusive, this may have been due to the fact that these 
two immunosuppressants were only used as adjuncts to the conventional 
rejection therapy. In an effort to evaluate the effectiveness of ATG 
alone, a prospective, randomized study was undertaken by Shield et ~· 
(163). Patients were initially treated with azathioprine and prednisone. 
With the onset of acute rejection, patients were randomly assigned 
additional treatment with either ATG or high-dose steroids. Eight of 
the ten patients treated with ATG had prompt reversal of acute rejection. 
The other two patients required high-dose steroids, with only one of 
the two patients regaining normal renal function. On the other hand, 
all of the patients treated with high-dose steroids experienced 
initial reversal of rejection. However, four required irradiation of 
the graft and actinomycin therapy; and, five of the other six experienced 
subsequent, second and third rejection episodes. A follow-up study 
(Mean post-transplant time of fourteen months) revealed that 9 of the 
patients treated with ATG had functional grafts, with 8 of the 9 
showing normal renal function. On the other hand, 9 of the 10 patients 
treated with high-dose steroids retained their grafts, but renal 
function remained impaired in three. 
IC. Goals of this Thesis 
The major obstacle facing the renal transplant patient 
is rejection of the donor organ. While a considerable amount 
of progress has been made in both the recognition of pre-clinical 
rejection and the treatment of rejection, a large percentage of 
renal transplant patients are subject to acute rejection from 
ineffective immunosuppression, Furthermore, this therapy can 
result in the inappropriate suppression of the recipient's immune 
system, leaving them vulnerable to infection. 
Therefore, there is a need for a test which will allow 
for the early prediction of impending rejection so that effective 
treatment can be carried out. In addition, the test must also 
allow for the more accurate accessment of the effects of 
immunosuppressive therapy. 
Secondly, it is the intention of this thesis to determine 
the effect of con A-pretreated peripheral blood lymphocytes 
(suppressor T-cells) from renal transplant patients on the 
blastogenesis of allogenic lymphocytes (resonder T-cells) isolated 
from a single, healthy volunteer. 
Finally, we plan to determine how pretransplant splenectomy, 
pretransplant transfusion, and anti-thymocyte globulin administration 
contributes to graft survival by analyzing the available data with 
respect to kidney function values, i.e. creatinine, BUN, and 
creatinine clearance, and serological values such as the total 
lymphocyte number, T-cell and B-cell number. 
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CHAPTER II 
MATERIALS AND METHODS 
IIA. General Materials and Sources 
Peripheral lymphocytes were obtained by consent from renal 
transplant and renal dialysis patients, and from healthy, adult 
volunteers at both Foster G. McGaw Hospital, Maywood, Illinois, and 
Hines Veterans Administration Hospital, Hines, Illinois. 
Culture media used in the experiments consisted of RPMI 1640 
(without antibiotics) supplemented with Hepes buffer solution (25 mM), 
Penicill.in/Streptomycin (10,000 units per ml and 10,000 meg per ml, 
respectively), L-Glutamine (20 mM) and heat inactivated fetal calf 
serum (10% v/v). All of the components of the culture media were 
purchased from Grand Island Biological Company. 
DNA inhibitor Mitomycin C was purchased from Aldrich Chemical 
Company. A stock solution (1.0 mg per ml sterile saline, 0.85% w/v) 
was made and frozen until the day of the experiment. On the day of 
the experiment, the Mitomycin C solution is diluted to 50 ~g per ml 
in Heper buffered (25 mM) RPM! 1640. 
Concanavalin A (Grade IV) and Phytohemagglutinin-P were 
t purchased from Sigma Chemical Company, and Defeo Laboratories, 
respectively. These two plant mitogens were made up to the desired 
concentrations in sterile saline, 0.85% w/v, and then frozen in 
1.0 ml or 5.0 ml aliquots until needed. 
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Lymphoprep, a ficoll-hypaque density gradient mixture was 
purchased from the Accurate Chemical and Scientific Corporation. 
Tritiated-methyl thymidine (2.0 ci/mmol) and Econofluor, a 
zylene-based scintillation fluor were purchased from New England 
Nuclear. Other materials used throughout the study will be mentioned 
in the "~lethods Section." 
liB. Methods 
IIB-1. Isolation of Peripheral Blood Lymphocytes 
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Peripheral blood lymphocytes were separated from fresh 
heparinized (14.4 units per ml) blood from renal transplant and renal 
dialysis patients, and from healthy, adult volunteers by Ficoll-hypaque 
density gradient centrifugation using a modification of the technique 
of Boytim (164). Briefly, 20 to 30 cc (6-8 cc per tissue culture tube) 
of whole blood was layered over 3.0 ml of Lymphoprep (specific density 
1.077 g per ml) in tissue culture tubes (Falcon 3033), and centrifuged 
for 30 minutes at room temperature at 1400 RP~1 (400 x gravity). After 
centrifugation, the top layer containing serum was carefully pipetted 
off up to the the white cell band (Figure 4). The white cell band 
which contains predorni natly lymphocytes was then removed vJi th a Pasteur 
pipet and placed in a clean tissue culture tube. The cells were then 
washed once in Hepes buffered (25 mt1)-RPHI 1640 by centrifugation at 
200 x gravity for 10 minutes and then they were counted. A Wright 
stain differential of the solution was carried out, and the cells were 
6 then diluted to a fi na 1 concentration of 1. 0 x 10 lymphocytes 
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LEGF.ND 
Figure 4. Separation of whole heparinized blood on a 
ficoll-hypaque density gradient 
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per ml of culture media. 
IIB~2. Determination of Lymphocyte Blastogenesis for Transplant 
Patients and Normal Adults Versus the Concentration of 
Concanavalin A. 
In order to determine the concentration of concanavalin A 
(con A) needed to elicit the greatest bastogenic response (recorded 
as counts per minute), a series of experiments were carried out 
using lymphocytes obtained from the peripheral blood of renal 
transplant patients or healthy, adult volunteers, as described in 
the preceeding section (Section II-Bl). To a series of micro titer 
wells lFalcon 3040}, 0.1 ml of the appropriate concentration of 
con A dissolved in Hepes buffered RPMI 1640, was added to a 0.1 ml 
patient or donor lymphocyte solution (1 x 106 lymphocytes/ml), 
bringing the final concentration of the mixture to 0.2 ml per well. 
Six determinations were C?rried out for each of the seven different 
concentrations of con A tested. The cells were then incubated for 
sixty-four hours at 37°C in a humidified atmosphere of 5% co2 
(Liquid Carbonics}. Eighteen hours before the termination of 
incubation, 1.0 pCi of (3H-methyl)-thymidine (2.0 Ci/mM) were 
added to each well. The cells were then harvested on glass fiber 
filter paper (Titertek Microtitration Equipment) using a multiple 
cell culture harvester (Skatron). The processed cells were allowed 
to dry overnight and then counted in 10 ml of econofluor in a 
refrigerated liquid scintillation counter (Searle Mark II LSC). 
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Results were recorded as percent stimulation. 
= Mean of individual count - control mean count 
Mean of highest count Percent Stimulation 
Control = 0 pg concanavalin A 
IIB-3. Preparation of Suppressor T Lymphocytes 
Peripheral lymphocytes isolated from renal transplant 
patients and healthy, adult volunteers are resuspended to a 
concentration of 1 x 106 lymphocytes per ml and split into two 
groups. The first group (suppressor T-cells) was incubated with 
an equal volume of con A (5.0 pg per ml hepes buffered RPMI 1640) 
in tissue culture multi-well plates (Linbro) in a humidified 
atmosphere of 5% co2 at 37°C for 44-48 ho~rs. After the incubation 
period, the cells were washed once, counted, and resuspended to a 
concentration of 1 x 106 lymphocytes per ml culture media. The 
cells were then incubated with an equal volume of Mitomycin C 
(50 pg/ml) 106 lymphocytes) at 25°C for 45 minutes. The cells 
werewashed twice and adjusted to a final concentration of 1 x 106 
lymphocytes per ml. The other group· of cells was prepared :in the 
same manner as the first group except that it is incubated in the 
absence of concanavalin A for the 44-48 hour incubation period. 
This second group of lymphocytes then acted a! the control group. 
IIB-4. Preparation of Responder T Lymphocytes 
Peripheral lymphocytes isolated from the same healthy, 
adult volunteer as described earlier (see IIB-l),were adjusted 
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5 to a final concentration of 5 x 10 lymphocytes per ml culture media. 
48 
These cells then act as responder cells to which the concanavalin A-
activated and non-concanavalin A-activated (control) cells will be 
added. 
IIB-5. Determination of Suppressor T-Cell Activity in Renal Transplant 
Patients and Healthy, Adult Volunteers by Mitogen Stimulation 
in Mixed Lymphocyte Culture 
The suppressor assay is carried out in the following manner: 
Lymphocytes were isolated from either transplant patients or healthy 
adults as described in Section IIB-1. To serve as an internal control, 
100,000 responder lymphocytes (lymphocytes isolated from a single, 
healthy adult) \'/ere added to the first two rov1s of the microtiter 
plates (see Figure 5). The next two rows consisted of 100,000 
responder lymphocytes plus 50,000 ConA-activated suppressor lymphocytes. 
The final two rows consisted of 100,000 responder lymphocytes plus 
50,000 control lymphocytes {lymphocytes obtained from patients or 
healthy adults which were not activated with Con A). To the appropriate 
well, either 10 ul of phytohemagglutinin-P (PHA-P)(100 ug/ml) or Con A 
(50 ug/ml or 500 ug/ml) was added for stimualtion of the responder 
lymphocytes. The plates \>Jere then incubated for four days at 37°C in 
a humidified environment of 5% co2. Eighteen hours prior to the 
termination of the incubation period, 10 ul of (3H-methyl)-thymidine 
(100 uCi/ml) were added to each well. The cells were then harvested 
on glass fiber filter paper, dried overnight, and counted in a liquid 
scintillation counter. Results are recorded as the percent suppression. 
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LEGEND 
Figure 5. Example of Mixed Lymphocyte Culture: 
Rows A and B contain 100,000 responder lymphocytes 
per well. 
Rows C and D contain 100,000 responder lymphocytes 
and 50,000 Con A-activated suppressor lymphocytes 
per well. 
Rows E and F contain 100,000 responder lymphocytes 
and 50,000 control lymphocytes per well. 
Rows 1 and 2 are not mitogen stimulated. 
Rows 3 and 4 are stimulated with 10 ul of PHA (100 
ug/ml) per well. 
Rows 5 and 6 are stimulated with 10 u1 of Con A 
(50 ug/ml) per well. 
Rows 7 and 8 are stimulated with 10 U1  of Con A 
(500 ug/ml) per well. 
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IIB-6. Effects of Splenectomy, Transfusion, and ATG on 
Acute Renal Allograft Rejection 
A retrospective study of 51 renal transplant patients ( 1 week 
to 7 years posttransplant) was undertaken to determine the effects of 
splenectomy, transfusion, and antithymocyte globulin (ATG) on graft 
acceptance. Data was collected and arranged so as to allow for 
the following comparisons of clinical values for: 
1) Patients experiencing acute rejection within one month 
of testing versus patients who have not suffered a 
rejection episode; 
2) Patients who on the test date had lymphocyte counts 
above 6000 versus patients with lymphocyte counts below 
6000. 
3) a) Splenectomized patients versus non-splenectomized 
patients. 
b) Transfused (pretransplant) patients versus 
non-transfused (pretransplant) patients. 
c) Patients receiving ATG versus patients who have not 
received ATG. 
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Data consist of both clinical test values as well as-immunological 
factors, The clinical tests used were creatinine, blood urea nitrogen 
(BUN), and creatinine clearance values. The immunological factors 
consisted of white blood cell count, total lymphocyte numbers, i.e. 
obtair1ed from whole blood or from Ficoll-hypaque gradient centrifugation, 
T and C:-cell values, and the effects of splenectomy, pretransplant 
transfusion, and ATG administration on graft survival and renal 
function. 
IIB-7. Statistical Analysis of Data 
Results of suppressor T-cells activity in both normals and 
patients, differences between acute rejection and non-acute rejection 
patients, and the various effects of sp 1 e·nectomy, pretranspl ant 
transfusion, and antithymocyte globulin administration on both renal 
function and serological function were calculated and statistically 
analyzed using the two sample, student's "t" test available through the 
Minitab II (165) computer program. 
Briefly, data for each experiment is entered into the 
appropriate column, which corresponds to a particular group. The 
computer then calculates the following parameters: 
m~l = population means group 
xlbar = sample mean group 1 
Sl = sample deviation group 1 
nl = sample size group 1 
m~2 = population mean group 2 
x2bar = sample mean group 2 
S2 = sample deviation group 2 
n2 = sample size group 2 
Next, the standard deviation of sample mean group 1 minus the sample 
mean group 2 is estimated by the following equation: 
S=SQRT (((l(S)-squared) (nl)+ ((52-squared) (n2)) 
Finally, a static T = (xl bar - x2 bar)/S is calculated, such that the 
static T has a t-distribution with degree of freedom given by 
df = (SQ (var 1 + var 2))) (SQ(var 1)/(nl-1) + 
{SQ (var 2)/(n2-l))) 
where var 1 = SQ (Sl)/nl and var 2 = SQ (S2)/n2 
The calculated 11 t 11 value is then compared to the established (table) 
11 t 11 value at a 95% confidence interval for the proper degrees of 
freedom. If the calculated 11 t" value is greater than the 11 t 11 value 
obtained from a t table, then the two groups being compared are 
considered to be significantly different at 0.05 levels of confidence. 
In order to determine the effect of splenectomy, pretransplant 
transfusion, and ATG administration on graft rejection, data was 
calculated and analyzed using the Chi Square (X2) test. 
The computer constructs a 2 x 2 table like the one shown 
below: 
Rejection Non-Rejection 
Splenectomy fo{fe1) fo(fe1) 
No Splenectomy fo(fe2) fo(fe2) 
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from the obtained frequencies (fo) an expected frequency (fe) is 
calculated by adding the two obtained frequencies across a now and 
then dividing by two: 
fe = fo 
row 1 + fo 1 /2 row 
column 1 column 2 
Chi Square is then calculated by taking the sum of the square of the 
differences of obtained and expected frequencies divided by the 
expected frequency for each case: 
2 
2 ( fo-fe) X = E ___ _ 
fe 
54 
The value obtained is then compared to a table value for the appropriate 
degrees of freedom: 
df = (r-1) (c-1) 
r = row 
c = column 
If the calculate x2 value is greater than or equal to the table value, 
then the two items being compared are considered to be significantly 
different at 0.05 confluence level. 
CHAPTER III 
RESULTS 
III. A Role for Suppressor T Lymphocytes in Renal Transplantation 
IIIA-1. Determination of Concanavalin A-Induced T Lymphocyte 
Proliferation 
Lymphocytes activated by concanavalin A have been shown to 
have a suppressive effect on cell-mediated and humoral immune responses 
in mice (20-22,166). Recently, normal human peripheral lymphocytes 
activated by concanavalin A have been shown to suppress the prolif-
erative response of similarly isolated lymphocytes to mitogens, 
antigens, and allogenic cells (167,168). 
Since we were interested in determining the suppressor cell 
activity in both healthy adults, as well as in renal transplant 
patients, it was necessary to determine the concentration of Con A 
which provided the greatest lymphocyte stimulation, i.e. activate 
suppressor cell activity. We first decided to carry out the suppressor 
cell experiments using 50 ug Con A/ml ·106 lymphocytes, since similar 
activations (167,168) had been carried out with Con A concentrations 
of between 40 to 60 ug/ml. While we obtained decent stimulation, we 
were losing a significant number of cells to the 48 hour Con A act-
ivation. Therefore, we decided to carry out the suppressor assay 
using three different concentrations (1, 5, and 10 ug/ml·106 cells) of 
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Con A. Two examples of our initial attempts to carry out the suppressor 
cell assay are shown in Figure 6. The results indicate that in both 
cases, Con A at 5 ug/ml afforded the greatest suppressor cell activity, 
i.e. decrease in counts per minute from cells cultured in RPM! 1640 
alone (control cells). However, in a series of subsequent experiments 
it was determined that the greatest stimulation, and hence generation 
of suppressor lymphocytes occurred when 25 ug/ml of Con A was used 
(Table 4). Since 25 ug/ml Con A gave the greatest stimulation for 
both patients and normals (Table 4), the data is normalized so that 
Con A at a concentration of 25 ug/ml has a stimulation index of 1.0, 
while all the other concentrations of Con A have values of less than 1.0. 
Finally, since a large portion of the work was carried out using 5.0 
ug/ml Con A, the remainder of the suppressor assays were also carried 
out using 5.0 ug/ml Con A to generate suppressor cell activity. 
IIIA-2. Suppressor Cell Activity in a Normal Population 
As shown in Table 5, the in vitro response of lymphocytes 
obtained from the peripheral blood of a healthy, adult volunteer to 
mitogen stimulation (PHA and Con A) was suppressed when cultured con-
comittantly with Con A pre-treated allogenic lymphocytes obtained from 
other adult volunteers. Similar results have been previously obtained 
by Shou et ~· (131) and Hallgren and Yunis (143). While both groups 
were able to demonstrate greater suppressor cell activity, this is 
probably due to the fact that they used twice the number of suppressor 
cells in the mixed lymphocyte culture assay. 
While suppressor cell activity appears to be the rule, there 
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LEGEND 
Figure 6. Two examples of early suppressor experiments using 
three different concentrations of Concanavalin A 
to generate suppressor cells. 
Key: Well A,B Non-stimulated responder cells only. 
C,D Suppressor Cells activated with RPMI 1640 
only (control) plus responder cells. 
E,F Suppressor Cells activated with Con A (1 ug/ml) 
plus responder cells .. 
G,H Suppressor Cells activated with Con A (5 ug/ml) 
plus responder cells. 
I,J Suppressor Cells activated with Con A (10 ug/ml) 
plus responder cells 
1,2 No mitogen stimulation 
3,4 PHA (100 ug/ml) 
5,6 Con A (50 ug/ml) 
7,8 Con A (500 ug/ml) 
Experiment I 
~ ~ 
Well 1,2 3,4 % Supp. 5,6 % Supp. 7,8 
§ 
A,B 1114 55368 11135 96390 
C,D 644 55700 39000 106384 
E,F 335 75300 -35 37600 4 73086 
G,H 1120 61400 -10 10873 72 69846 
l,J 603 71600 -29 12200 68 85305 
Experiment II 
~ ~ 
Well 1,2 3,4 % Supp. 5,6 % Supp. 7,8 
A,B 1176 79618 42633 59772 
C,D 1584 81791 33528 57829 
E,F 2389 64947 21 23601 30 50092 
G,H 664 56338 31 21344 36 65102 
l,J 343 93233 -14 27398 18 96718 
~ Columns E,F, G,H, or I,J 
% Suppression = 1 - Column C,D X 
§ 
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~ 
% Supp. 
31 
34 
20 
~ 
% Supp. 
13 
-13 
-67 
100 
Each result represents the average of four wells (runs) 
TABLE 4 
DETERHINATION OF LYMPHOCYTE BLASTOGENESIS FOR TRANSPLANT 
PATIENTS AND NORMAL ADULTS VERSUS THE CONCENTRATION OF 
a 
CONCANAVALIN A 
b c 
Concentration Con A (ug/ml) Normals Patients 
d d 
0 0.01 + 0.01 0.06 + 0.06 
1 ND 0.13 + 0.14 
5 0.31 + 0.10 0.52 + 0.18 
12.5 0.81 + 0.14 ND 
25 1 1 
e 
33.3 0.46 + 0.14 0.96 + 0 
50 0.08 + 0.02 0.81 + 0.47 
a 
b 
Culture conditions were as follows: zero point one ml of 
normal or renal transplant patient's lymphocytes (1 x 106 
lymphocytes per ml) in culture media are incubated with 
an equal volume of the appropriate mitogen at 37°C for 
44 - 48 hours in a 5% C02 environment. Sixteen hours 
prior to the termination of the experiment, 0.01 ml of 
3H-methyl thymidine is added to each well. The cells are 
then harvested, dried overnight, and counted. The results 
are expressed as percent stimulation. 
The normal group consisted of 9 people. 
c 
The patient group consisted of 8 people. 
d 
Results are normalized for 25 ug per ml of concanavalin A. 
e 
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This piece of data represents only a single experiment, 
where all other results represent at least four experiments. 
* Uncertainty is expressed as + 1.0 S.D. 
Table 5 
Effect of Con A-Treated Allogenic Lymphocytes on the Mitogenic Response of Normal Human Lymphocytes 
Responding Con A eH)Tdr incorporation(cpm) in response to mitogens 
cells Pretreatment 
subjects* of allogenic PHA lOo]Jg CON A soHa CON A 500~ 
cell"s§ ml ml ml 
cpm % inh cpm % inh cpm % inh 
1 + 55689 + 14203 -17 3302 + 353 34 63256 + 4825 12 
47317 + 10979 4985 + 1338 71548 + 11912 
2 + 14678 + 7159 85 5107 + 354 65 47400 + 22370 44 
92377 + 955 14524 + 6801 84282 + 9483 
3 + 91752 + 274 -20 3811 + 1391 69 64804 + 13597 18 
76867 + 14491 10357 + 4236 79077 + 13820 
4 + 70496 + 5137 26 3472 + 267 37 64177 + 10720 16 
95319 + 5334 5052 + 705 76727 + 17041 
5 + 39781 + 17009 -10 3590 + 1446 -150 444 77 + 11349 0 
35798 + 13690 1438 + 447 44642 + 8849 
6 + 23994 + 4954 21 1502 + 269 37 25851 + 11349 8 
30441 + 11639 2498 + 780 28454 + 8849 
-
7 + 22691 + 4881 8 1175 + 256 23 29049 + 170 38 
24322 + 4822 1009 + 65 46962 + 1458 
8 + 16483 + 2652 -9 5237 + 938 -14 14812 + 2349 15 
15391 + 5337 4927 + 1237 17450 + 2417 
9 + 31081 + 2652 5 5047 + 1750 3 26899 + 1685 23 
32381 + 8919 502g- + 1002 34624 + 2646 m 
0 
TABLE 5 
(continued) 
Table 5 Effect of Con A-Treated Allogenic Lymphocytes on the 
~·1i togeni c Response of Norma 1 Human Lymphocytes. 
* 1.0 ~ 106 normal donor lymphocytes were mixed with 5.0 
x 10 t·1itomycin C-treated allogenic control or suppressor 
cells in RPMI 1640 plus the appropriat~ mitogen. The 
cells were then labeled with 1uCi of ( H-methyl)-
thymidine and counted. 
§Allogenic suppressor cells and allogenic control cells 
were incubated in RPMI 1640 plus or minus {+ or -) 
Con A (5 ug/ml/106lymphocytes), for 44 - 48 hours. 6Cells \·Jere washed, treated with Mitomycin C (50 ug/ml/10 
lymphocytes), and then washed §gain. The cells were 
resuspended, and then 5.0 x 10 lymphocytes were added 
to the appropriate well in quadruplicate. 
Uncertainty is expressed as + 1.0 S.D. 
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were a few instances as seen in our results as well as those of Shou 
et al. (131) in which stimulation was noted as opposed to suppression. 
In addition, suppressor cell activity was most pronounced when Con A 
was the stimulating mitogen. It should be emphasized that all the 
blastogenic activity could be attributed to the responder cell, since 
the allogenic, Con A-pretreated suppressor cells had been treated with 
mitomycin C, which prevented them from undergoing blastogenesis when 
exposed to mitogen stimulation in mixed lymphocyte culture. Evidence 
that this was the case was demonstrated by the fact that Con A pre-
treated lymphocytes demonstrated only minimal counts of 200 to 2000 
cpm which is similar to those of non-pretreated, non-stimulated 
lymphocytes; whereas cultures containing responder cells had counts 
ranging from 30,000 to 200,000 cpm. 
IIIA-3. Suppressor Cell Activity in Renal Transplantation Patients 
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Since other groups (99,127) have suggested that suppressor cells 
may play a role in renal allograft tolerance, we decided to look at the 
suppressor cell activity in renal transplant patients who were at 
various stages in their posttransplant history. Using the mixed 
lymphocyte culture assay, as we had previously done for the normal 
population, we divided the transplant patients into:four groups based on 
their test date, i.e. time from transplant date to when the mixed 
lymphocyte culture was carried out. The results in Table 6 show a 
pattern of suppressor cell activity in which the initial activity is 
low, then increases, then decreases, and finally is the greatest for 
patients who have retained their transplant for at least one year 
TABLE 6 
Suppressor Effect of Concanavalin A-Treated Lymphocytes from the Peripheral Blood of Renal 
Transplant Patients on the Mitogenic Response of Peripheral Blood Lymphocytes from a 
Single Healthy Donor(Responder) 
a Mitogens Used in the Assay 
Time Posttransplant Phytohemagglutinin-P Concanavalin A 
(100 ug/ml) (50 ug/ml) (500 ug/ml) 
0 - 3 months 9 + 17 11P = 0.55 -18b+ 65 11P = 0.37 -18b+ 53 11P = 0.30 
(Group I) N = 9 p = 0.00* N = 9 p = 0,89 N = 9 p = 0.37 p = 0.10 p = 0.04* p = 0.10 
3 - 6 months 16 + 32 p = 0.00* 4 + 33 p = 0.63 3 + 26 p = 0.76 
(Group II) N = 11 p = 0.52 N = 11 p = 0.01* N = 11 p = 0.23 
6 - 12 months -19b+ 12 p = 0.00* -13b+ 12 p = 0.17 0 + 18 p = 0.11 
(Group III) N = 7 N = 7 N = 7 
Greater than 12 months 24 + 19 38 + 22 16 + 19 
(Group IV) N = 11 N = 11 
~ata is reported as percent suppression = 1 -
b 
N = 11 
cpm ConA-treated lymph - cpm NS lymph·. 
cpm control lymphocyte - cpm NS lymph. 
11Negative number represents stimulation Statistical significance calculated using student's "t" test and reported in the follow-
ing manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; Group II 
vs. Group III; Group II vs. Group III: Group III vs. Group IV. 
* §Statistically significant at P < 0.05 
Uncertainity expressed as± 1.0 S.D. 
,C ICC 
0'1 
w 
(Group IV, Table 6). This pattern is observed for both Con A (50 and 
500 ug/ml) and PHA (100 ug/ml). While it was not surprising that 
the suppressor cell activity was greatest in patients who had retained 
their graft for at least one year (Group IV, Table 6), the decrease 
in suppressor cell activity in transplant patients who had their graft 
for between 6 to 12 months {Group III, Table 6) was unexpected. 
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Unlike the results for the normal population, suppressor cell 
activity in transplant patients was greatest when PHA was the stimulating 
mitoger .. In addition, there was greater statistical significance between 
the four groups when PHA was the stimulating mitogen. 
One fact which is evident is the degree of variability 
displayed by the results. The issue of variability for the mixed 
lymphocyte assay has been noted by others· (143, 144), and will be 
elaborated on in the Discussion Section. To lessen the effect of 
variability and thus prevent a particular group from being unequally 
weighted with respect to time from transplant, experiments were carried 
out in a randomized manner. Thus, on any given day, a patient 6 months 
posttransplant was tested along with a patient 2 years posttransplant. 
It should be noted that the same patient may appear in more than one 
group, because he or she was tested at different times in their post-
transplant history. Moreover, none of the patients that began in the 
study dropped out due to graft rejection. 
It should be pointed out that experiments were carried out 
on transplant patients undergoing acute graft rejection to determine 
suppressor cell activity; however, we were unable to complete these 
experiments because of excessive lymphocyte loss, either at the 
initial isolation step or after the 44-48 hour incubation with 
concanavalin A (suppressor cell activation) (See Discussion). 
IIIA-4. Effect of Splenectomy, Pretransplant Transfusion, and 
Antithymocyte Globulin on Suppressor T-cells 
Transplant patients for who the mixed lymphocyte culture assay 
was carried out, were arranged into four paired groups to determine 
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the effect of splenectomy, pretransplant transfusion, and antithymocyte 
globulin (ATG) on suppressor cell activity. While individual 
differences exist for an individual group and mitogen, there was no 
particular pattern nor statistical significance whether or not splen-
ectomy, pretransplant .transfusion, antithymocyte globulin administration 
or combinations of these therapeutic measures were utilized. 
IIIB. Acute Rejection and Non-Rejection 
JIIB-1. Comparison of Renal Transplant Patients Experiencing Acute 
Rejection and Renal Transplant Patients Not Experiencing 
Acute Rejection 
In order to determine the differences in renal function, 
serology, and effectiveness of three therapeutic measures, i.e. 
splenectomy, pretransplant transfusion, and antithymocyte globulin 
administration between transplant patients experiencing acute renal 
rejection and those showing no signs of acute rejection, a 
retrospective study was undertaken. 
TABLE 7 
Effect of Splenectomy, Transfusion, and Antithyrnocyte(ATG) Administration on 
Renal Transplantation of Transplant Patients with Good Renal Function as 
Judge by the MLC Suppressor Assay 
Therapy Mitogens Used 
Splenectomy 
No Splenectomy 
(Group I) 
Antithyrnocyte Globulin 
No Antithyrnocyte Globulin 
(Group II) 
Transfusion(Pretransplant) 
No Transfusion 
(Group III) 
Splen. and Transfusion 
No Splen. and Transfusion 
(Group IV) 
Group I 
Group II 
Group III 
Group IV 
PHA 100 ~ 
ml 
0.18 + 0.30 
0.04 + 0.22 
N = 21, 17 
-0.01 + 0.23 
0.17 + 0.27 
N = 13, 26 
0.02 + 0.24 
0.18 + 0.28 
~ 
N = 16, 23 
0.03 + 0.26 
0.14 + 0.27 
N = 
p = 0.1046 
p = 0.0323* 
p = 0.0613 
p = 0.2541 
CONA 50~ 
ml 
-0.16 + 0.65 
0,19 + 0.34 
N = 21, 16 
0.13 + 0.39 
-0.04 + 0.63 
N = 13, 26 
CONA 500 ~ 
ml 
0.01 + 0.35 
0.02 + 0.15 
N = 20, 17 
0.04 + 0.17 
0.04 + 0.32 
N = 13, 25 
-0.15 + 0.54 -0.01 + 0.23 
- -0.14 + 0.55 0.07 + 0.31 
- -
N = 16, 23 N = 16, 22 
-0.28 + 0.58 -0.06 + 0.25 
- -0.10 + 0.51 0.07 + 0.28 
N = N = 
p·= 0.0458* 
p = 0.3072 
p = 0.1059 
p = 0.0757 
p = 0.4712 
p = 0.9899 
p = 0.3333 
p = 0.1596 
0'1 
0'1 
TABLE 7 
(continued) 
a cpm Con A-treated lymphocytes - cpm NS lymphocytes 
Data is recorded as percent suppression = 1 - -----------------------------------------------------
b 
Negative number represents stimulation. 
@ 
cpm control lymphocytes 
times 100. 
Statistical significance is calculated u·sing the student's "t" test. 
* 
fl 
Statistically significant at P < 0.05. 
Uncertainty is expressed as + 1.0 S.D. 
- cpm NS lymphocytes 
Ol 
..... 
As shown in Table 8, transplant patients experiencing acute 
rejection had renal function values indicative of deteriorating renal 
physiology; whereas patients showing no signs of acute rejection had 
values in the normal range (Table.9). These findings were expected 
since a large part of the diagnosis of acute rejection is based on 
the renal function values. 
Another finding was that patients experiencing acute rejection 
had significantly (P < 0.05) lower lymphocyte numbers whether they 
were obtained from whole blood (clinical), or by Ficoll-Hypaque 
density gradient centrifugation (experimental). In addition, these 
patients had significantly lower T cell numbers. B cell numbers were 
also noticeably lower, but not significantly (Table 10). This was 
probably due to the small population of rejection patients. 
Finally, acute rejection patients had noticeably (P < 0~05) 
fewer splenectomies, fewer pretransplant transfusions, and were less 
often treated with antithymocyte globulin (Table 11). 
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The mean time posttransplant, i.e. time from transplant to tast 
date, was 8.0 months with a range of 0.3 months to 36 months for the re-
jection group (Group I). This compares to a mean posttransp1ant time of 
17.3 months with a range of 1.0 to 79 months for the non-rejection group. 
The male to female ratio was six to one (12 males to 2 females) for the 
rejection group (Group I); while the ratio for the non-rejection group 
(Group II) was 26 males to 4 females. Lastly, the blood profiles 
(A, B, AB, 0, and not available) were quite different for the two groups 
TABLE 8 
a Comparison of Renal Function Tests of Renal Transplant Patients Experiencing 
Acute Rejection Versus Renal Transplant Patients With Good Renal Function 
Renal Function Acute Rejection b No Rejection b Probability c 
Tests (Group I) (Group II) 
Creatinine 3.2 + 1.2 1.5 + 0.4 p = o.oooow 
N = 16 N = 112 
BUN 49.2 + 23.0 21.1+7.7 p = o.oooow 
N = 15 N = 113 
1Cteat. Clearance 33.3 + 12.3 73.1 +:25.5 p = o.oooow 
N = 15 N = 102 
a Renal Function Test values obtained from transplant patients at both Foster 
bG. McGaw Hospital and Hines VA Hospital. 
Acute rejection is defined as whether or not the patient was treated as suggested 
by the findings of clinical and diagnotic evaluations. 
c 
wStatistical significance calcul!ated using student's "t" test. 
§Test is significant at P < 0.05 
Uncertainty stated as+ 1.0 SD 
0'1 
'-0 
TABLE 9 
a . b b b Normal Values for Total Lymphocyte Numbers , Creatin1ne , BUN , and Creatinine Clearance 
Test Normal Value Method 
Total Lymphocyte Number 9 0.06 to 5.5 x 10 /liter Whole Blood smear and Wright 
stain differentialc 
d Creatinine 
BUNd 
Male: 
Female: 
Male: 
Female: 
0. 9-1.5 mg/ 100ml 
0.8-1.2 mg/100ml 
0.6-1.2 mg/100ml 
0.5-1.0 mg/100ml 
7-18 mg/100ml 
Nonspecific Method 
Specific Method 
d Creatinine Clearance Male: 105 + 20 ml/min. 
95 + 20 ml/min. 
117 + 20 ml/min. 
108 ±: 20 ml/min. 
Nonspecific Method 
Female: 
Male: Specific Method 
Female: 
a Simmons, Arthur, Technical Hematology (3rd edition). 1980. J,B, Lippincott 
b Company, Phil. Penn. Chpt. III, pp. 93-150, 
Faulkner, W.R., and King, J.W., Renal Function Test in Fundamentals of Clinical 
Chemistry. Tietz, N.W., ed. W.B. Saunders Company, Phil. Penn, Chpt. 12, 
pp. 698-742 (1970). 
c Total Lymphocyte Number = Total White Cell Count/100 x Percent lymphocytes 
by differential ~alues found in appendix of Fundamentals of Clinical Chemistry, Tietz, N.W. (ed.) 
"" 0 
TABLE 10 
Comparison of Serological Tests of Renal Transplant Patients Experiencing 
Acute Rejection Versus Renal Transplant Patients with Good Renal Function 
a Serological Tests 
Lymphocyte Number 
Clinical d 
Experimental e 
T-cell Number f 
B-cell Number f 
b Acute Rejection 
(Group I) 
598 + 568 
N = 14 
5.0 + 2.5 
N = 16 
111 + 94 
N = 13 
96 + 192 
N = 13 
b No Rejection 
(Group II) 
1263 + 920 
N = 111 
9.6 + 6.7 
N = 110 
407 + 430 
N = 93 
191 + 252 
N = 91 
Probabilityc 
p = o.oooow 
p = o.oooow 
p = o.oooow 
p = 0.1285 
a Serological Test values obtained from renal transplant patients at Foster G. McGaw and 
bRines VA Hospital. 
Acute rejection defined as whether or not the patient was treated in accordance with 
both clinical and other diagnostic findings. 
~Statistical Significance calculated using student's "t" test. 
Total lymphocyte number calculated from whole blood by the following formula: 
e Lymphocyte number x Percent Differential = Total Lymphocyte Number 
Lymphocytes obtained by Ficoll-hypaque density gradient centrifugation and calculated as 
ffor clinically derived total lymphocyte number. 
WT- and B-cell numbers obtain by Erythrocy§e Rosetting Technique. 
Test is significant at P < 0.05 Uncertainty stated as + 1.0 S.D. 
....... 
...... 
TABLE 11 72 
a,b . Comparison of Two Groups of Renal Transplant Patients 
for Three Types of Immune Therapy 
I Th A R . • a N j i b 2c mmune erapy cute e]ect1on o~re ect on X 
(Group I) (Group II) 
Splenectomy 3.71 21% 50% 
N = 14 N = 38 
43% 61% Pretransplant 1.46 
Transfusion 
N = 14 N = 38 
29% 38% Anti-thymocyte 0.39 
Globulin(ATG) 
N = 14 N = 38 
aPatients experiencing acute rejection of graft at or 
baround the time(one month) of testing. 
n 
Patients showing no signs of rejection at or near(one 
month) the time of testing. 
~Statistical Significance calculated using x2 • 
Statistically significant using a value of less than 5.0 
for one degree of freedom. 
(Table 12). Age differences are also computed (Table 12). 
III. Effects of Three Different Forms of Therapy on Renal Allograft 
Survival. 
IIIC-1. Effects of Splenectomy on Kidney Function and the Lymphocyte 
Population 
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Renal transplant patients were divided into four groups on the 
basis of whether or not they had their spleen removed, and whether or 
not they were experiencing acute rejection. As can be seen in Table 13, 
patients not experiencing acute rejection had renal function values 
which were very comparable, whether or not they had their spleen removed. 
In addition, the renal function values for the non-rejection group was 
significantly different from the rejection group. Since none of the 
patients currently experiencing acute rejection had a splenectomy, 
there are no values for Group III (Splenectomized, rejection patients). 
It should be pointed out that four of the patients who had a 
splenectomy suffered a rejection episode early in their transplant 
history. However, three of these patients had excellent functioning 
grafts at the time of testing, while the fourth suffers from chronic 
rejection. Therefore, these four patients were counted as splenect-
omized, non-acute rejection patients (Group I, Tables 13 and 14). Thus, 
in Table 11, where we are interested in determining the effect of splen-
ectomy, pre-transplant transfusion, and ATG administration on preventing 
acute rejection; thus, the patients were divided into two groups on the 
basis of whether they have ever-experienced an acute rejection episode, 
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TABLE 12 
Comparison of the Mean Time Posttransplant, Male to Jemale Ratio, 
and Blood Types for Acute Rejection. and Non-Rejection Transplant 
Patients 
Characteristics Acute Rejection Non-Rejection 
(Group I) (Group II) 
Mean Time Post- 8.0 + 13.7 months 17.3 + 17.0 months 
transplanta 
= 37b 131b N N = 
Range 0.3 to 36 months 1.0 to 79 months 
Male/Female 12/2 26/4 
Age 45.2 + 10.7yearsC 38.7 + 11.5 yearsc 
Blood Profile 
Type A 7 10 
B 3 5 
AB 0 1 
0 3 9 
N.A.d 1 9 
a 
Represents the mean time from transplant to test date. 
b 
Represents the number of tests 
c 
Represents the patient's age as of 
d 
Value not available 
* Uncertainty expressed as+ 1.0 S.D. .Significant at P 0.05 
TABLE 13 
a b 
Comparisons Between Splenectomized and Non-Splenectomized Renal Transplant Patients 
c 
For Three Renal Function Tests. 
Renal Function 
Tests 
Splenectomized 
Non-Rejection 
Patients 
(Group I) 
Non-Splenectomized 
Non-Rejection 
Patients 
(Group II) 
Splenectomized 
Rejection 
Patients 
(Group III) 
d 
Non-Splenectomized Probability 
Rejection 
Patients 
(Group IV) 
Creatinine 1.4 + 0.4 1.5 + 0.4 
e 
N.A. 3.2 + 1.2 p = 0.2218 
N= 90 N = 61 
BUN 21.4 + 7.0 22.1 + 8.2 
N = 90 N = 61 
e 
N.A. 
N = 17 
48.9 + 22.3 
N = 16 
p = 0.0000* 
p = 0.0000* 
p = 0.6085 
p = 0.0000* 
p = 0.0000* 
Creat. Clearance 70.1 + 23.4 71.6 + 25.4 
e 
N.A. 34.1 + 12.3 p = 0.7025 
p = 0.0000* 
N = 83 N = 59 N = 16 p = 0.0000* 
a 
Spleen removed prior to the transplant. 
b 
c 
Splenectomized and non-splenectomized patients maintained on different, individualistic 
immunosuppressive regimes. In addition,patients may have also received transfusions and/o.r 
ATG treatment. 
Renal Function Test values obtained from transplant patients at both Foster G. McGaw Hospital 
and Hines V.A. Hospital. 
-....! 
(.)'1 
TABLE 13 
(continued) 
d 
Statistical significance calculated using student's "t" test and reported in the following manner: 
Group I vs Group II, Group I vs Group IV, and Group II vs Group IV for each test. 
e 
* 
None of the patients currently (within one month of the test) experiencing rejection had a 
splenectomy. 
Test is significant at P ~ 0.05 
Uncertainty is expressed as± 1.0 S.D. 
N represents the number of tests 
"-J 
m 
TABLE 14 
a b 
Comparisons Between Splenectomized and Non-Splenectomized Renal Transplant Patients 
For Lymphocyte Numbers, T-Cell Numbers, and B-Cell Numbers 
c 
Serological Test Splenectomized 
Non-Rejection 
Patients 
(Group I) 
Non-Splenectomized 
Non-Rejection 
Patients 
(Group II) 
Splenectomized 
Rejection 
Patients 
(Group III) 
d 
Non-Splenectomized Probability 
Rejection 
Patients 
(Group IV) 
e 
Lymphocyte Number 1569 + 977 1135 + 680 
g 
N.A. 580 + 552 p = 0.0020* 
- p = 0.0000* 
N = 88 N = 57 N = 15 p = 0.0029* 
f 
T-Cell Number 496 + 477 472 + 420 
g 
N.A. 110 + 94 p = 0. 7741 
p = 0.0000* 
N = 71 N = 46 N = 13 p = 0.0000* 
f 
B-Cell Number 218 + 259 128 + 201 
g 
N.A. 96 + 192 p = 0.0369* 
p = 0.0604 
N = 72 N = 45 N = 13 p = 0.6074 
a 
Patients had their spleen removed prior to their transplant. 
b 
c 
d 
Splenectomized and non-splenectomized patients maintained on different, individualistic 
immunosuppressive regimes. In addition, patients may have also received transfusions and/or 
ATG treatment. 
Serological Test values obtained from renal transplant patients at both Foster G.McGaw Hospital 
and Hines V.A. Hospital. 
Statistical significance calculated using student's "t" test and recorded in the following manner: :::1 
TABLE 14 
(continued) 
Group I vs Group II, Group I~ Group IV, and Group II vs Group IV for each serological value. 
e 
Total Lymphocyte Number = Total White Blood Cell Count/100 x Percent Lymphocytes from Differential. 
f 
T-cell and B-cell numbers calculated using an erythrocyte-resetting technique in the following 
g 
* 
manner: 
T-Cell Number = Total Lymphocyte Number x Percent T-Cells 
None of the patients currently (within one month of the test date) experiencing a rejection 
episode had a splenectomy. 
Test is significant at P< 0.05. 
Uncertainty is expressed as+ 1.0 S.D. 
N refers to the number of tests 
-....,J 
00 
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and then analyzed for the individual therapeutic modality. On the other 
hand, in Tables 13, 14, 16, 17, 19, and 20 we are interested in the con-
tribution that the particular therapeutic measure had on the renal 
physiology of the transplant patient at or near (within one-year) the 
time of testing. Therefore, these tables contain several patients 
who have suffered a rejection episode early in their transplant history, 
but within one-year of testing had excellent functioning grafts, and no 
further rejection episodes. 
Non-splenectomized, non-rejection transplant Jtients exhibited 
significantly (P < 0.05) fewer total lymphocyte numbers and 8-cell 
numbers than the splenectomized, non-rejection transplant patients 
(Table 14). The T-cell numbers were practically the same for the two 
groups. Total lymphocyte numbers, T- and 8-cell numbers for the non-
splenectomized, rejection patients were significantly (P < 0.05) less 
than either of the two groups (Groups I and II). 
Statistical analysis, i.e. student's "t" test, showed that both 
splenectomized and non-splenectomized groups (Groups I and II) of non-
rejection transplant patients were comparable (P > 0.4) with regards 
to the mean time posttransplant (Table 15). The mean time posttrans-
plant for the non-splenectomized, rejection group (Group IV) was sig~ 
nificantly (P < 0.05) less than either of the non-rejection groups 
(Groups I and II, Table 15). 
IIIC-2. Effect of Pretransplant Transfusion on Renal Allograft 
Function and on Lymphocyte Number 
For the purpose of analySis, renal transplant patients were 
TABLE 15 
Comparison of Mean Time Posttransplant, Male to Female Ratios, and Blood Types for 
Splenectomized Non-Rejection, Non-Splenectomized Non-Rejection, and Non-Splenectomized 
Rejection Transplant Patientsa 
Characteristics 
Mean Time Post-
Transplant 
Range 
Male/Female 
Blood Profile 
Type A 
B 
AB 
0 
NAc 
Splenectomized 
Non-Rejection 
Patients 
(Group I) 
17.5 + 16.9 months 
N = 90 
1 - 60.0 months 
19/4 
8 
1 
0 
8 
6 
Non-Splenectomized 
Non-Rejection 
Patients 
(Group II) 
15.7 + 17.0 months 
N = 63 
0.3- 79 months 
19/4 
7 
6 
1 
4 
5 
Non-Splenectomizedb 
Rejection Patients 
(Group III) 
1.8 + 0.6 months 
N = 17 
0.2 - 5 months 
5/1 
3 
1 
0 
1 
1 
a Splenectomized and non-splenectomized renal transplant patients at both 
bFoster G. McGaw Hospital and Hines V.A, Hospital. 
None of the patients experiencing rejection had a splenectomy. 
c §Values not available. 
Uncertainty expressed as± 1.0 S.D. 
N refers to the number of tests 
co 
0 
TABLE 16 
Comparison of Renal Transplant PatientsaReceiving Pretransplant Transfusions b and 
Those Not Receiving Pretransplant Transfusions 
Renal Function Transfused Non- Non Transfused Transfused Non-Transfused Probabilityc 
Test Rejection Patient Non-Rejection Rejection Rejection 
Patient Pabient Patient 
(Group I) (Group II) (Group III) (Group IV) 
Creatinine 1.3 + 0.4 1.6 + 0.4 3.6 + 0.7 3.0 + 1.3 p = 0.0000* 
-
N = 77 N = 72 N = 5 N = 12 p = 0.0018* p = 0.0000* 
p = 0.0030* 
p = 0.0028*. 
p = 0.2789 
BUN 21.1 + 7.7 21.2 + 8.4 66.0 + 26.0 41.1 + 16.2 p = 0.9945 
N = 78 N = 72 N = 5 N = 11. p = 0.0185* p = 0.0024* 
p = 0.0186* 
p = 0.0025* 
p = 0.1056 
Creat. Clearance 76.1 + 26.3 67.1 + 17.8 33.5 + 8.6 34.2 + 13.6 p = 0.0188* 
N = 73 N = 67 N = 4 N = 12 p = 0.0002* p = 0.0000* 
p = 0.0022* 
p = 0.0000* 
p = 0.9027 
~enal Function Test values obtained from renal transplant patients at both Foster G. 
bMcGaw Hospital and Hines V.A. Hospital. 
Transfusions consisted of whole blood, red blood cells, packed red blood cells, washed 
cells, plasma, and combinations of the five. 
cStatistical significance calculated using student's "t" test and reported in the following 
manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; Group II vs. 
* Group III; Group II vs. Grou~ IV; and Group III vs. Group IV. 
Test is significant at P < 0.05. Uncertainty expressed as + 1.0 S.D. 
(X) 
...... 
TABLE 17 
a Comparison of Renal Transplant Patients Receiving Pretransplant Transfusions b 
and Those Not Receiving Pretransplant Transfusions 
Serological Test Transfused Non- Non-Transfused Transfused Non-Transfused Probabilityc 
Rejection Patients Non-Rejection Rejection Rejection 
Patients Patients Patients 
(Group I) (Group II) (Group III) (Group IV) 
Total LymHhocyte 1242 + 957 1464 + 837 528 + 462 599 + 601 p = 0.1374 
Number p = 0.0496* 
T-Cell Number 
B-Cell Number 
N = 75 N = 70 N = 4 N = 10 p = 0.0073* 
p = 0.0205* 
p = 0.0007* 
p = 0.8162 
e 439 + 449 550 + 455 122 + 119 99 + 86 p = 0.1896 
N = 64 N = 53 N = 4 N = 10 .p = 0.0030* p = 0.0205* 
p = 0.0007* 
p = 0.0000* 
p = 0.7467 
e 186 + 253 181 + 227 61 + 51 36 + 38 p = 0.9108 
N = 65 N = 52 N = 4 N = 9 p = 0.0065* p = 0.0000* 
p = 0.0091* 
p = 0.0001*. 
p = 0.4453 
aSerological values obtained from transplant patients at both Foster G. McGaw Hospital 
band Hines V.A. Hospital. 
Transfusions concisted of whole blood, red blood cells, packed red blood cells, washed 
blood cells, plasma, and combinations of the five. 
cStatistical significance calculated using student's "t" test and reported in ·the 
following manner: Group I vs. Group II; Group I vs •. Group III; Group I vs. IV; Group II 
vs. Group III; Group II vs. Group III; and Group III vs. Group IV. 00 
N 
d 
TABLE 17 
(continued) 
Total lymphocyte number calculated from whole blood in the following manner: 
Total lymphocyte number = Total White Blood Cell Count/100 x Percent of lymphocytes 
by differential 
e 
*T-cell and B-Cell numbers calculated by e~ythrocyte-rosetting technique. 
Statistically significant at P < 0.05. Uncertainty expressed as ± 1.0 S.D. 
00 
w 
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divided into four groups on the basis of whether or not they had received 
a pretransplant blood transfusion, and whether or not they had currently 
(within one-year) suffered a rejection episode. Transfusions consisted 
of either whole blood, red blood cells, packed red blood cells (148), 
washed cells, or combinations of the four. 
As was the case with splenectomized patients (Section IIIC-1), 
there are several patients who had a rejection episode early in their 
transplant history, but at the time of testing had normal functioning 
grafts. Therefore, these patients were counted as non-rejection patients. 
The results in Table 16 show non-rejection, pretransplant trans-
fused patients exhibited significantly (P < 0.05) lower creatinine values 
than the non-rejection, non-transfused transplant patients. In addition, 
creatinine clearance values were also significantly different for the 
same two groups. Blood Urea Nitrogen (BUN) values on the other hand, 
were not statistically different (P = 0.1945) for the two groups (Groups 
I and II). Significance differences (P < 0.05) are seen between Groups 
1 and II, I and IV, II and III, and II and IV, Table 16. While creatin-
ine and creatinine clearance values are similar--for the two rejection 
groups, BUN values are noticeably lower in the non-transfused group 
(Group IV). 
Total lymphocyte, T-cell, and B-cell numbers are statistically 
similar for non-rejection patients, whether or not they were trans-
fused (Groups I and II, Table 16) prior to transplant. Again statist-
ical differences of (P < 0.05) are seen between non-rejecting groups 
(Groups I and II) and rejection groups (Groups III and IV), whether or 
not either group received a pretransplant transfusion. Lymphocyte 
numbers, T-cell, and B-cell numbers appear to be equivalent for both 
rejection groups (Groups III and IV}. 
The mean time from transplant to test date for both transfused 
and non-transfused (pretransplant) patients are almost identical 
(P = 0.94).{Groups I and II, Table 18). Statistical differences of 
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P = 0.00 in the mean time posttransplant are noted between the non-
rejecting groups (I and II) and rejecting groups (III and IV) (Table 18). 
Finally, the t~o rejection groups (III and IV) have similar posttrans-
plant times (P > 0.5). The representative blood types, and male to 
female ratios are also shown in Table 18. 
IIIC-3. Effects of Anti-Thymocyte Globulin (ATG) Administration on 
Renal Allograft Function and on Total Lymphocyte, T-Cell, and 
B-Cell Numbers 
Non-rejection transplant patients have similar creatinine, BUN, 
and creatinine clearance values whether they received ATG or not (Table 
19). Again, as was the case for splenectomized and pretransplant, 
transfusion patients, patients currently experiencing a rejection 
episode (Groups III and IV) have significantly (P < 0.05) poorer renal 
function values than the non-rejection patients.(Groups I and II). Renal 
function values for the two rejection groups (III and IV) are measureably 
different. Patients who experienced a rejection episode within one month 
of the test date and had received ATG have decidedly lower creatinine 
and BUN values, and statistically higher creatinine clearance values than 
rejection patients who did not receive ATG. 
As was the case for both-_splenectomy and transfusion data, 
TABLE 18 
Comparison of Mean Time Posttransplant, Male to Female Ratio, and Blood Types 
for Pretransfused Non-Rejection. Non-Transfused Non-Rejection, Transfusion 
Rejection, and Non-Transfused Rejection Transplant Patients 
Characteristics Transfused Non-
Rejection Patients 
(Group I) 
Non Transfused 
Non-Rejection 
Patients 
(Group II) 
Transfused 
Rejection 
Patients 
(Group III) 
Non-Transfused 
Rejection 
Patients 
(Group IV) 
Mean Time Post-
a transplant 
16. 1 + 15. 2 months 17. 8 + 18. 6 months 2. 3 + 1. 3 months 1. 7 + 1. 4 months 
Range 
Male/Female 
Blood Profile 
Type A 
B 
AB 
0 b 
N.A. 
. -
N = 82 N = 74 
1 - 58.0 months 
22/4 
9 
3 
1 
11 
3 
1 - 79 months 
14/6 
5 
4 
0 
2 
9 
~Represents the mean time from transplant to testing. 
§Values not available. 
Uncertainty expressed as + 1.0 S.D. 
N refers to the number of-tests. 
N = 4 
1 - 4 months 
2/0 
0 
1 
0 
0 
1 
N = 12 
0.2 - 5 months 
3/1 
3 
0 
0 
0 
1 
co 
0'1 
TABLE 19 
Comparison of Renal Transplant Patients Receiving Antithtymocyte Globulin(ATG) and Those 
Not Receiving ATGa 
Renal Fugction 
Test 
ATG-Nonrejection 
Patients 
No ATG 
Non-Rejection 
Patients 
(Group II) 
ATG-Rejection 
Patients 
No ATG 
Rejection 
Patients 
(Group IV) 
Probabilityc 
(Group I) (Group III) 
Creatinine 1.5 + 0.4 
N = 52 
1.5 + 0.6 
N = 101 
2.6 + 0.2 
N = 4 
3.4 + 1.3 
N = 12 
p = 0.6391 
p = 0.0000* 
p = 0.0000* 
p = 0.0000* 
p = 0.0001* 
p = 0.0608 
BUN 22.8 + 7.8 
N = 51 
22.0 + 10.1 
N = 99 
43.0 + 0.8 
N = 4 
51.5 + 26.9 
N = 9 
p = 0.6254 
p = 0.0000* 
p = 0.0056 
p = 0.0000* 
p = 0.0048* 
p = 0.3219 
Creat. Clearance 71.9 + 28.2 
N = 45 
70.8 + 21.3 
N = 98 
48.0 + 3.9 
N = 4 
27.9 + 9.5 
N = 11 
p = 0.8075 
p = 0.0000* 
p = 0.0000* 
p = 0.0000* 
p = 0.0000* 
p = 0.0000* 
:Horse Anti-Human Thymocyte Globulin 
Renal Function Test values obtained from renal transplant patients at both Foster G. 
McGaw Hospital and Hines V.A. Hospital. 
cStatistical significance calculated using student's "t" test and reported in the 
following manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; 
* Group II vs. Grou~ III; Group II vs. Group IV; Group III vs. Group IV. 
Test is significant at P < 0.05 Uncertainty expressed as ± 1.0 S.D. 
00 
-...I 
patients who have not experienced a rejection episode within one-year 
of the test date, are considered as non-rejection transplant patients. 
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Both non-rejection groups (I and II) have similar lymphocyte, 
T-cell, and 8-cell numbers (Tab1e 20). The values for the two rejection 
groups (III and IV) are decidedly less than those for the non-rejection 
groups (I and II) (Table 20), with only the lymphocyte number for the 
rejection which received ATG not being significantly different from 
the two non-rejection groups. Finally, rejection patients who 
received ATG demonstrated greater lymphocyte and T cell numbers than 
the rejection group (Group IV) which did not receive ATG (Table 20). 
8 cell numbers for the two rejection groups (III and IV, Table 20) 
are statistically comparable (P = 0.68). 
The mean time posttransplant for the two non-rejection groups 
(l and II} are approximately the same (Table 21). The mean time post-
transplant for rejection patients whom were treated with ATG (Group IV, 
Table 21} is significantly shorter than either non-rejection group 
(Group I and II). Since there was only a single individual who 
received ATG and experienced a rejection episode within one-year of 
testing, this category (Group III --- ATG, Rejection Transplant 
Patients) is not subject to statistical analysis. Finally, male to 
female ratios, and the blood types of all ATG-treated, and non-ATG-
treated transplant patients are also presented in Table 21. 
TABlE 20 
a Comparison of Renal Transplant Patients Receiving ATG and Those Not Receiving ATG 
Serological Test b ATG-Non No ATG Non- ATG No ATG Probabilityc 
Rejection Rejection Rejection Rejection 
Patients Patients Patients Patients 
(Group I) (Group II) (Group III) (Grpup IV) 
Total Lymphocyte d 1411 + 958 1358 + 892 909 + 577 514 + 562 p = 0.7357 
Number N = 48 N = 95 N = 3 N = 11 p = 0.2970 p = 0.0004* 
p = 0.3241 
p = 0.0005* 
p = 0.3682 
T- Cell Number e 504 + 465 457 + 462 198 + 89 94 + 90 p = 0.6101 
N = 40 N = 79 N = 2 N = 11 p = 0.0252* p = 0.0000* 
p = 0.0865 
p = 0.0000* 
p = 0.3718 
B-Cell Number 164 + 260 182 + 216 30 + 38 47 + 46 p = 0.7043 
N = 39 N = 77 N = 2 N = 10 p = 0.0240* p = 0.0106* 
p = 0.0249* 
p = 0.0000* 
p = 0.6793 
~orse anti-human thymocyte globulin. 
Serological Test values obtained from transplant patients at both Foster G. McGaw 
Hospital and Hines V.A. Hospital. 
cStatistical significance calculated using student's "t" test and reported in the 
following manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; 
OJ 
1.0 
Group II vs. Group III; Group II vs. Group IV; and Group III vs Group I~ 
TABLE 20 
(continued) 
dTotal Lymphocyte Number = Total White Cell Count/100 x Percent Lymphocyte by differential. 
e 
*T-cell and B-cell number calculated using erythrocyte-rosetting technique. 
§Test is significance at P < 0.05 
Uncertainity expressed as ± 1.0 S.D. 
1..0 
0 
TABLE 21 
Comparison of Mean Time Posttransplant, Male to Female Ratios, and Blood Types 
for ATG-Non-Rejection , No ATG-Non-Rejection, ATG-Reje~tion, and No ATG-
Rejection Transplant Patients 
Characteristics ATG No ATG ATG No ATG 
Non-Rejection Non-Rejection Rejection Rejection 
Patients Patients Patients Patients 
(Group I) (Group II) (Group III) (Group IV) 
Mean Time P~st­
transplant 
15.1 + 15.1 mo. 17.~ + 18.1 mo. 2.5 + 1.3 mo. 1.5 + 1.3 mo. 
Range 
Male/Female 
Blood Profile 
Type A 
B 
AB 
0 
c N.A. 
N = 53 
1.5 - 56 mo. 
17/1 
6 
3 
0 
6 
3 
- -
N = 97 
0.25 - 79 mo. 
21/8 
8 
4 
1 
7 
9 
N = 5 
0.5 - 4 mo. 
0 
0 
0 
0 
1 
0 
N = 12 
0.25 - 5 mo. 
4/1. 
3 
1 
0 
0 
1 
a ATG administered and non-ATG administered transplant patients obtained from both 
bFoster G. McGaw Hospital and Hines V.A. Hospital. 
Time from transplant to testing. 
c §Values not available 
Uncertainty expressed as ± 1.0 S.D. 
N refers to the number of tests 
0.0 
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CHAPTER IV 
DISCUSSION 
IVA. Suppressor T-Lymphocytes 
IVA-1. Suppressive Effects of Concanavalin A-Treated 
Allogenic Lymphocytes on Normal Human Lymphocytes 
in a One-Way Mixed Lymphocyte Culture (MLC) 
Every person goes through life surrounded by potentially harm-
ful microorganisms. Those that invade the body are usually kept in 
check by the body's immune defenses, an elaborate system that stands 
geared to intercept and destroy foreign cells (170). At the same 
time, an individual's immune system must not react too vigorously to 
invasion by these microorganisms. Finally, an individual's immune 
system must be capable of recognizing self from nonself, so as not to 
destroy the body's own cells. Therefore, it has become increasingly 
evident that the immune system possesses a mechanism(s) of checks and 
balances, so it can prevent the excessive reaction to a multitude of 
stimulations throughout the lifetime of that individual. 
The role of antigen-specific and mitogen-activated (non-
specific) suppressor lymphocytes in the regulation of humoral and cell-
mediated immune responses has been previously demonstrated (16, 20, 57-
63). In addition, lymphocytes isolated from spleen and activated by 
Concanavalin A have been shown to inhibit the antibody response of 
plaque-forming cells (PFC), mixed lymphocyte culture reaction (MLC) 
92 
and the generation of cytotoxic cells in cell-mediated lympholysis 
(CML) (20-22). 
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Like suppressor cells isolated from the central immune tissue 
of mouse, peripherally blood-derived lymphocytes also appear to exhibit 
suppressive actions. Evidence has been accumulated implicating sup-
pressor cells isolated from peripheral blood as being involved in the 
etiology and pathogenesis of a number of pathologic states (66-68, 
171-173). Thus, if suppressor cells represent a mechanism for modula-
ting immune responses, and are found in the peripheral blood of 
individuals experiencing several disorders, then one might also expect 
to find suppressor cells in the peripheral blood of normal, healthy 
individuals. 
Indeed, our data shows (Table 5) that Con A-pretreated lympho-
cytes isolated from the peripheral blood of healthy, adult volunteers, 
suppress the proliferative response of similarly isolated allogenic 
lymphocytes. These findings confirm the earlier work of Shou et al. 
(167) and Hallgreen and Yunis (169). 
Since blastogenesis with non-specific mitogens, such as phy-
tohemagglutinin (PHA) and Concanavalin A (Con A) can involve either B 
or T lymphocytes, our results do not distinguish whether the suppres-
sive effects were due entirely to the inhibition ofT-cell prolifer-
ation. However, work by Shou et al. (167) with pokeweed mitogen 
(PWM), a potent B-cell stimulator, shows less suppressive activity 
(Figure 7) than the T-cell mitogens Con A and PHA; and this suggests 
that the suppressor cells act mainly at the level of the T-cell. 
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LEGEND 
Ffgure 7. Effect of Con A-Treated Allogenic Lymphocytes on 
the Mitogenic Response of Normal Human Lymphocytes 
from Table 1 of Suppressor Cell Activity after Concan-
avalin A Treatment of Lymphocytes from Normal Donors, 
Shou et ~- (167}. 
L{) 
en 
Responding 
Cells (sub-
jects)* 
1 
2 
3 
4 
5 
6 
7 
8 
Con A 
Pretreatment 
of allog~nic 
Cells~ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
-
+ 
( 3H) TdR II1_ce>_rporation (cpm) in Response toMi togens4= 
PHA Con A PVM 
cpm % inh. cpm % inh. cpm % inh. 
87,828 + 6,684 13.8 121,521 + 4,213 27.2 37,349 + 369 18.6 
75,742 + 5,566 88,444 + 6,356 30 '40 1 + 2 '89 7 
74,450 + 3,270 49.5 65.035 + 3,227 46.3 13' 136 + 354 -6.4 
. 37,576 + 653 34,945 + 1,753 13,979 + 1,026 
126,324 + 5,395 28.4 85,958 + 2,878 32.4 44,285 + 1,700 38.4 
9> ~479 + 3,772 57,860 + 519 27,285 + 372 
73,138 + 3,056 18.0 94,328 + 3,366 44.1 15,583 + 1,319 1.7 
59,999 + 2.375 52,759 + 1,717 15,312 + 467 
38,650 + 2,850 27.0 128,362 + 6,229 24.8 11,445 + 688 -61.6 
28,215 + 1,417 96,491 + 1,266 18,493 + 1,384 
93,639 + 2,850 37.3 188,524 + 4,585 37.7 21,278 ± 629 2.0 
58,501 + 2,903 117,377 + 5,896 20,857 + 1,521 
43,991 + 3,244 39.7 125,332 + 4,969 44.9 19,778 + 2,068 46.7 
26,553 + 392 69,036 + 888 10,539 + 713 
60 '334 + 6 '856 36.8 146,836 + 6,190 49.7 12,390 + 515 -29.1 
38,119 + 554 73,787 + 3,172 16,001 + 835 
* 5.0 x 104 normal donor lymphocytes were mixed with an equal 
number of MC-treated allogenic control or suppressor cells in 
RPMI plus designated mitogen and labeled with 2 uCi (3H)thymidine 
((~)TdR) as described inKaterials and Methods. Each pair of 
cultures consists of responder lymphocytes from a different 
subject donor. 
:j: 
0 
Allogenic lymphocytes were incubated in RPMI plus or minus Con A 
(60·.ug/ml) for 48 hr. Cells were washed, treated with MC 
(50 ug/ml) for 30 min, washed again, and resuspended in RFMI. 
5.0 x 104 allogenic cells were added to each culture well. 
Counts per minute of (3H)TdR incorporated represents the mean of 
3 -4 replicate cultures + the standard deviation 
96 
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Additional evidence that normal, healthy adults possess sup-
pressor cells capable of inhibiting cell-mediated immune responses, 
comes from experiments utilizing the same lymphocyte, i.e., autolo-
gous lymphocytes, as the responder and suppressor cells. Shou et al. 
(167) and Jayavant et al. (73), have shown that lymphocytes pretreated 
with Con A suppressed the proliferative response of autologous lympho-
cytes. We have also attempted several suppressor experiments using 
autologous lymphocytes, but have only a single experiment to show for 
these efforts. The one experiment did show (data not shown) that 
incubation of lymphocytes with autologous Con A-pretreated lymphocytes 
resulted in a 20% suppression of the lymphocyte proliferative response. 
These observations are consistent with a model which proposes that 
individual stimuli are prevented from initiating an uncontrolled 
immunologic chain reaction through the intervention of suppressor cells 
capable of abrogating the response (167). 
Another factor to be considered is whether the inhibition of 
proliferative responses is entirely due to suppressor cells, or possi-
bly due to cytotoxic cells acting directly on the responder lympho-
cyte, and thus preventing its proliferation, i.e., blast formation 
as measured by the uptake of 3H-thymidine. Several lymphocyte stimu-
lators, such as PHA and allogenic and xenogenic (originating from a 
different species) antigens have been shown to elicit immunospecific 
cytotoxicity (174). However, studies by Perlmann et al. (175) have 
shown that Con A not only fails to generate such cytotoxicity, but it 
can even inhibit PHA-induced cytotoxic effects. Thus, it appears that 
most humans possess a population of suppressor lymphocytes which, when 
activated by Con A, can suppress both cell-mediated and humoral immune 
responses. 
Finally, as seen in our studies, and as noted by other groups 
(167, 173)~ a few examples of stimulatory activity have been observed 
in the mixed lymphocyte reaction assay. The failure to manifest sup-
pressor activity may be attributed to the presence of stimulatory 
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non-T lymphocytes and other non-lymphocylic cells in the mixed lympho-
cyte reaction mixture. Semenzato et al. (176) has demonstrated the 
existence of non-T-cells, lacking the C3 (Complement 3) receptor, which 
are capable of stimulatory lymphocytes, and thus decreasing or even 
abrogating the effects of suppressor T-cells. Another possible ex-
planation for the lack of suppressor activity might involve a Con A 
receptor. Shou et al. has suggested that ·can A can act through more 
than a single receptor; one site responsible for triggering blast 
transformation, and another for initiating suppressor activity. Thus, 
cells which fail to be induced to manifest suppressor functions, but 
can undergo blast transformation, may lack a second receptor. Subse-
quent studies have shown suppressor lymphocytes to be a non-prolifera-
tive cell, i.e., does not require blast transformation for its activity 
{177, 178). Therefore, a more plausible explanation might be that the 
individual failing to manifest suppressor activity, might lack or 
possess ineffective suppressor T lymphocytes; and the resulting stimu-
lation might be due to Con A-stimulation of lymphoproliferative species 
able to realize their full potential in the absence of suppressor 
activity. Finally, the lack of suppression in those few examples might 
merely reflect the physiological state of the individual on that given 
day. Individuals exposed to a stressful situation, s~ch as running 
(179), have been shown to possess lymphocytes which exhibit reduced 
responsiveness to the mitogens PHA and Con A. In addition, it is also 
possible that stress which elevates plasma cortisol levels, decreases 
both T and B-cell levels in circulation (179, 180); and this in turn 
contributes to the diminished suppressor activity of peripherally-
obtained blood lymphocytes. 
IVA-2. Suppressive Effects of Concanavalin A-Treated 
Allogenic Lymphocytes on Lymphocytes Obtained 
from Renal Transplant Patients with Good Renal Function 
Suppressor cell activity exhibited by renal transplant patients 
experiencing good renal function, follows ·the pattern exhibited by the 
Normal group (Table 5), but the overall suppressor cell activity dis-
played by the transplant group was decidedly less than that of the 
Normal group. While the two groups differ with respect to physical 
characteristics such as age and probably renal function, i.e., creati-
nine, creatinine clearance, and BUN, the major reason for the decrease 
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in suppressor cell activity is that the transplant patients are receiving 
exogenous steroids. Several groups have previously shown that 
corticosteroids administered both in vitro (181) and in vivo (181-186), 
suppress the response of lymphocytes to stimulation by mitogens and 
antigens, and enhanced the generation of antibody-secreting cells possi-
bly by inhibiting suppressor cells (187-189). Clarke et al. (186) 
showed that prednisolone suppressed the mitotic response of lymphocytes 
to sub-maximal stimulating doses of PHA, four hours after prednisolone 
administration, returning to normal by twenty-four hours. Finally, 
Duclos et al. (190) showed that transplant patients receiving daily 
doses of azathioprine (2-3 mg/kg) and prednisolone (0.25 mg/kg), had 
significantly less suppressor activity (37 percent ~ 14 percent) than 
+ . 
normal volunteers (89 percent- 6 percent), as JUdged by the Jerne 
plaque assay, i.e., a measure of antibody-forming cells/106 collected 
cells. As for the mechanism of steroid action, the evidence suggests 
that steroids act directly on the suppressor T-cells (189,190). 
An unexpected finding of our study with renal transplant 
patients is the pattern of suppressor cell activity exhibited by the 
different posttransplant groups (Table 6). If, in fact, suppressor 
T-cells do play a major role in graft survival, then one would expect 
to see increasing suppressor cell activity with the increasing period 
of graft retention. However, instead of increasing, the suppressor 
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cell activity for the six-to-twelve-month group of patients (Group III, 
Table 6) decreased. While the decrease is only statistically signifi-
cant (p <0.01) when PHA is the stimulating mitogen, the pattern is the 
same for both concentrations of Con A. In an effort to explain these 
findings, one has to consider the effect of experimental (design), change 
in drug therapy, or physiological factors as being responsible for the 
decrease in suppressor cell activity. If all the patients in the 
six-to-twelve-month group were tested at the same time, this might 
explain the decrease in suppressor cell activity. However, the experi-
ments were carried out in a random manner, i.e., a patient in one time 
group was tested along with patients from one of the other time groups; 
thus, it is unlikely that this type of experimental error is responsible 
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for the observed pattern of suppressor cell activity. The second ex-
planation, changes in drug therapy, also does not totally explain the 
observed pattern of suppressor activity, since steroid administration 
remained constant or decreased after the initial three months post-
transplant. It should be noted that changes in the dosage of Imuran 
(azathioprine) occurred throughout the different posttransplant periods 
for some of the patients; and these changes may have contributed to 
the observed decreased suppressor cell activity seen in the six-to-
twelve-month group. Therefore, it appears that the decrease in sup-
pressor cell activity might reflect a change in the immune status of 
those patients; however, the nature of these changes is unknown at this 
time. 
IVA-3. Suppressor T Cell Activity in Renal Transplant 
Patients Undergoing Acute Rejection of the 
Kidney Graft 
One of the goals of this thesis was to determine the role of 
suppressor T-cells in acute rejection, and determine whether the assay 
used to measure suppressor activity could be used to predict impending 
acute rejection. However, we were unable to obtain results of this type 
due to the requirement for large numbers of lymphocytes needed to 
carry out the experiments, i.e., 12 x 106 lymphocytes per patient. 
In addition, we were involved in another study of recently-transplanted 
patients, and thus their availability to our study was limited. 
In a recent study of allograft rejection, Jayavant et al. 
(73) demonstrated that suppressor activity paralleled renal function. 
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In a prospective study of living-related recipients, .they found that 
patients who were experiencing acute rejection and/or had subsequent 
(1-3 months posttransplant) loss of their graft, suppressed the proli-
feration of autologous lymphocytes by 33 to 77 percent; whereas, 
transplant patients with good renal function (creatinine of less than 
1.5 mg/dl) had suppressor cell activity measured at 88 to 98 percent. 
A retrospective study of cadaver recipients showed a suppression of 
greater than 85 percent to be typically associated with excellent long-
term allograft function. In contrast, patients with suppressor cell 
activity of less than 80 percent, were shown to have experienced graft 
rejection. When the successes (excellent allograft function) from 
both living-related recipients and cadaver recipients were combined, 
they were shown to have a composite suppressor cell activity of 89.5 
percent, as compared to a suppressor cell activity of 51 percent for 
the failures (graft rejection or loss) for both groups, P < 0.05 
When the two groups were compared for their ability to suppress allo-
genic lymphocyte proliferation, a similar pattern of suppressor cell 
activity was observed, but the two groups (successes vs. failures) 
were not significantly different. In addition, the results were simi-
lar, only the magnitude being different, whether the suppressor cell 
was treated or not with Con A. While this study demonstrates a rela-
tionship between magnitude of suppressor cell activity and renal allo-
graft function, definitive conclusions cannot be made because of the 
high degree of variability of the test results, and the small patient 
population. Thus, there appears to be a role for suppressor cells in 
the prevention of renal allograft rejection; however, more sophisticated 
tests are needed to accurately access the role of suppressor cells in 
the rejection process. 
IVB. Evaluation of the Effects of Three 
Therapeutic Modalities on Renal Allograft 
Function and Survival 
IVB-1. Effectiveness of Pretransplant Splenectomy 
in Renal Allograft Function and Survival 
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Since Starzl and his coworkers (125, 126) first suggested that 
splenectomy might represent an additional method for preventing acute 
rejection, several studies have been undertaken (127-131). While a 
majority of the studies have found splenectomy to be ineffective in 
enhancing graft survival, our findings support those of Kauffman et al. 
(131), who showed that splenectomy carried out prior to transplantation 
enhanced graft survival. 
ficant at P · < 0.05, 
Our results, which are statistically signi-
show that only three of the thirty-one patients 
(9.7 percent) who underwent a splenectomy suffered a rejection episode, 
while eleven of forty patients (27.5 percent) who did not undergo a 
splenectomy, suffered at least one rejection episode. These results are 
similar to Kauffman's group (131), who found that 93 percent of the 
patients who underwent pretransplant splenectomy and 81 percent of the 
patients who had their spleen removed at the time of transplant, did not 
experience a rejection episode; whereas, 48 percent of the patients not 
undergoing splenectomY suffered at least one acute rejection episode. 
An earlier study by Berne et al. (191) had presented evidence that) 
while not statistically significant, was highly suggestive of improved 
one-year-graft survival with pretransplant splenectomY; sixty-six 
percent one-year-functional-graft survival with splenectomy, as 
compared to forty-nine perecnt without splenectomy. 
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These findings contradict the earlier studies of Bennett et ~­
l128) and Opelz and Terasaki (129), who observed no significant diff-
erence in the occurence of rejections, whether or not a patient had a 
splenectomy. However, their conclusions were based on splenectomy being 
carried out at the time of transplanatation; this procedure has sub-
sequently been shown by Kauffman and his coworkers (131) to be ineffect-
ive in enhancing graft survival. Furthermore, several of the studies ·an 
the effectiveness of splenectomy for graft survival were carried out in 
tne early 1960's, when many of the graft failures were attributable to 
sepsis and ineffectual management of the immunosuppressed patient. 
A second point raised by our studies is that splenectomy appears 
to be without influence on the renal function of transplant patients 
wnom have not experienced a rejection episode within one-year of the 
test date (Table 13). In addition, transplant patients who have 
suffered a rejection episode early in their posttransplant history, but 
at the time of testing had excellent functioning grafts, have stat-
istically eqivalent (P > 0.5) renal function values whether or not 
splenectomy was carried out. However, this does not preclude the 
possibility that splenectomy had a positive effect early on the renal 
function and survival of these patients. 
An interesting finding of our studies is that patients who had 
a splenectomy and have normal renal function, have significantly greater 
total lymphocytes ( P = 0.00) and B-cells ( P = 0.04 ) , than 
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similar patients who did not undergo splenectomy. T-cell numbers for 
both groups (Groups I and II, Table 14) are almost identical. Similar 
results have been reported by Veith et al. (127) and Bischel et al. 
(192). Bischel and her colleagues showed that both the white blood 
cell count and azathioprine dosage of twelve patients who had undergone 
splenectomy was significantly higher on the thirtieth post-transplant 
day, than fifteen patients who had not undergone splenectomy. 
The mechanism by which splenectomy appears to improve renal 
allograft survival is as yet unknown; however, it appears that splenec-
tomy might exert its suppressive effects on both the humoral and cel-
lular arms of the rejection process. The possibility that splenectomy 
interferes with immunoregulatory responses to the graft has been sugges-
ted by Enomoto and Lucas (193); however, their proposal does not appear 
to be supported by other studies in rodents (194, 195), or by clinical 
surveys (127, 129}. While it is possible that splenectomy interferes 
with regulatory interactions of various suppressor T lymphocytes on the 
one hand, and effector T lymphocytes and B lymphocytes on the other, 
the overall effect of splenectomy appears to be a reduction in the 
strength of the rejection response (195). 
The mechanism whereby the humoral immune response is suppressed 
might be that the spleen is an important site for antigen trapping and 
clonal proliferation, i.e., proliferation of antibody-producing cells 
(195). Thus, under normal conditions, antigens in circulation are 
trapped by the spleen where they can invoke the proliferation of anti-
body-producing cells. However, after splenectomy, there is no spleen 
to trap the antigens, and they are subject to degradation by the liver. 
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Evans et ~- (195) have attempted to test this hypothesis by diverting 
venous return from the graft directly into the portal circulation; 
however, graft survival was not improved by this procedure. It is 
possible that to degrade these antigens, several passages through 
the liver are required. 
IVB-2. Enhancement of Renal Allograft Function and Survival with 
Pretransplant Transfusion 
Since the report by Opelz and Terasaki (132) first showed 
that blood transfusions were effective in improving renal allograft 
survival, a majority of studies now confirm that transfusions given 
prior to transplantation improve graft survival. Studies in our 
laboratory show that patients who did not' undergo transfusion prior 
to transplantation were twice as likely to experience a rejection 
episide (eight out of thirty patients or twenty-seven percent), as 
patients who had a pretransplant transfusion (six out of forty 
patients or fifteen percent). Similar results have been obtained 
by Hunsicker et ~- (144). They showed that patients who had a 
pretransplant transfusion exhibited a graft survival rate of 
seventy-nine percent at three months, seventy-one percent at the 
end of one year, and fifty-five percent at the end of three years 
post-transplant. This compared to a survival rate of fifty-five 
percent at three months, forty-four percent at one year, and thirty-
six percent at the end of three years for patients who did not 
undergo a pretransplant transfusion. 
Since their study was retrospective and not randomized, a 
comparison of transfused and nontransfused patients was carried out 
to determine if other factors such as age and sex of the allograft 
recipient were responsible for the improved graft survival observed 
in the transfused group. While significant differences were observed 
between the two groups, stratification of Hunsicker's data (Figure 8) 
for these factors, as well as for the influence of the original 
cause of renal failure and the transplant date, still showed a 
strong correlation between transfusion and graft survival. While 
our study of additional factors was not as extensive as that of 
Hunsicker et ~- (144), we also found that neither the age, nor sex 
of the graft recipient was significantly responsible for the 
improved graft survival. Thus in the cas·e of cadaver transplants, 
transfusion(s) appear to exert a positive effect. 
In the case of living-related transplants, Solheim and his 
co-workers (142) have demonstrated superior graft survival in 
transfused patients with one-mismatched halotype (halotype refers 
to a HLA antigen); whereas, blood transfusions given to patients 
with HLA-antigens identical to the graft donor, appear to be 
without influence. In a similar study, Solheim and co-workers 
(196) have shovm this to also be the case in cadaver transplants. 
In an attempt to explain this findings, Keown and Descampes (197) 
have proposed that the beneficial effects of transfusion are mediated 
by strong 11 non-specific 11 immunological effects. However, at this 
time there is insufficient data to support or refute their 
hypothesis. 
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Figure 8. Comparison of Non-transfused and Transfused Patients 
from Table 1 of Effect of Blood Transfusions on Cadaver 
Renal Allograft Survival, Hunsicker et ~· (144). 
Comparison of Nontransfused and Transfused Patients 
No Transfusions Transfusions Probability 
No. of Patients 42 109 
Age§ 31 + 13 35 + 12 
* 
Male/Female 33/9 70/39 
* 
Months on Dialysis§ 9.7 + 10.7 15 .8 + 15 .o 0.02 
Bilateral Nephrectomy 3/42 44/109 0.002 
Pretransplant Hematocrit § 25 % + 7 20 % + 6 0.001 
Pretransplant WBC§ 6200 + 2000 7200 + 3400 
* 
HLA Ag Mismatches§ 2.6 + 1.13 2.21 + 0.99 
* 
Cytotoxic Ab (> 10 %) 2/42 13/109 
* 
Immediate Graft FUnction 38/42 71/109 0.004 
*. 
Differences not statistically significant 
§ 
-Means given + 1 SD 0 1.0 
Another interesting finding of our results is that both the 
creatinine and creatinine clearance values for transfused, non-
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rejecting patients (Group I, Table 16) were significantly better than 
thos~ of the nontransfused, nonrejecting patients (Group II). Since both 
groups contained patients who had experienced an acute rejection epi-
sode early in their transplant history. but at the time of testing had 
excellent functioning grafts, their values were independently accessed 
(i.e., transfused, early, acute rejection patients and nontransfused, 
early, acute rejection patients) to determine if they were responsible 
for the differences in creatinine and creatinine clearance values 
(Table 16). However, evaluation of the latter groups (Groups III and 
IV, Table 22), indicates that their values are not significantly 
different from the former groups (Groups 'r and I I, respectively, 
Table 16); and, therefore, it appears that the difference in creati-
nine and creatinine clearance values for transfused and nontransfused, 
nonrejection patients, can be attributed to the beneficial effects of 
pretransplant transfusion. Blood Urea Nitrogen (BUN) values were 
similar for both nonrejection groups, as were the lymphocyte, T-cell 
and B-cell numbers (Tables 16 and 17). 
While a majority of the studies support the practice of ad-
ministering transfusions prior to the transplant, there appears to be 
a discrepancy over what number of transfusions provide the maximum 
benefit. Our results (Table 23) show that the number of transfusions 
had no effect on whether or not a patient suffered a rejection epi-
sode. However, only two of the fourteen patients who suffered a 
rejection episode subsequently lost their kidney; and eight of the 
TABLE 22 
~ 
Comparison of Renal Blnction \alues fot the Effects of Pretransplagt 
Transfusion on Early, Acute Rejectiona and Non-Rejection Patients 
Renal function 
Test 
Creatinine 
BUN 
Creat. Clearance 
a 
Transfused 
Non-Rejection 
Patients 
(Group I) 
1.3+0.4 
N = 77 
21.1 + 7.7 
N = 78 
76.1 + 26.3 
N = 73 
Non-Transfused 
Non-Rejection 
Patients 
(Group II) 
1.6 + 0.4 
N = 72 
21.2 + 8.4 
N = 72 
67.1 + 17.8 
N = 67 
Transfused 
Early Acute Re-
jection Patients 
(Group III) 
1.3+0.6 
N = 4 
26.5 + 12.4 
N = 4 
55.5 + 22.0 
N = 4 
Non-Transfused 
Early Acute 
Rejection Patients 
(Group IV) 
1.8 + 0.4 
N = 11 
29.5 + 8.5 
N = 11 
61.9 + 16.8 
N = 11 
Groups III and IV represent patients who experienced an acute rejection episode early in 
b 
their transplant history, but at the time of the test date (within one month of the test) 
had excellent functioning grafts. 
Values obtained from Table 16 
N refers to the number of tests 
........ 
........ 
........ 
TABLE 23 
Effects of Transfusion on Acute Rejection 
Transfusion Rejection 
Pre-transplant 21.5 
During transplantation 7.0 
Post transplantation 14.3 
Not transfused 14.3 
Pre- and During 7.0 
transplantation 
Pre- and Post 21.5 
transplantation 
During and Post 14.3 
transplantation 
Pre-, During, and Post 0 
transplantation 
Transfused once 0 
Twice to five times 58.0 
Greater than five times 42.0 
a 
Fourteen patients in this group 
b 
a 
% 
% 
% 
% 
% 
% 
% 
% 
% 
% 
% 
Thirty-seven patients in this group 
c 
Twelve patients in this group 
d 
Twenty-four patients in this group 
Non-Rejection 
b 
29.7 % 
5.4 % 
2.7 %-
35 .1 % 
5.4 % 
16.2 % 
2.7% 
2.7 % 
d 
8.3 % 
50.0 % 
41.7 % 
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fourteen had normal renal function at the time of the test. Hunsicker 
et al. (144) found that maximum graft survival at three months post-
transplant occurred with as few as three units of blood. Feduska et al. 
(152) reported maximum beneficial effects with five transfusions. On 
the other hand, other studies have shown that maximum graft survival 
occurs with larger numbers of transfusions. In a study made by the 
National Institute of Allergy and Infectious Diseases (NIAID) which 
included more than 1,500 patients and some forty medical centers, one-
year graft survival was shown to increase from 37 percent in patients 
who had received no transfusions, to 50 percent in patients who had 
received one to five transfusions, and to 56 percent in patients re-
ceiving six to ten transfusions (198}. Opelz and his coworkers (146) 
demonstrated significant beneficial effects with more than twenty 
transfusions. 
Finally, Solheim and coworkers (142) found that, whereas 
cadaver transplant survival was influenced by the number of transfusions 
(196), the number of blood transfusions in living-related transplants 
did not influence graft survival. 
In addition to the number of transfusions which a prospective 
transplant patient receives, another factor which has been investigated 
for its possible effect on graft survival is the nature of the blood 
transfused. Whereas, Opelz and Terasaki (150) found frozen blood to be 
less effective than packed cells or whole blood, Polesky et al. (199), 
and Hunsicker et al. (144), found there was no difference in the out-
come between patients receiving frozen erythrocytes and those receiving 
other blood preparations. While our study did not examine the effect 
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of the different blood types on graft survival, it should be pointed 
out that patients who received multiple transfusions received a number 
of different blood transfusion types, depending on their physiological 
and/or immunological status. 
One final factor which may have an affect on graft survival 
is the blood type of the recipient who is receiving the pretransplant 
transfusion. A study made by Joysey et al. (200) found that the bene-
ficial effect of transfusion was restricted to patients of the blood 
group 110. 11 Bore et al. (201) found a significant improvement in the 
one-year-graft survival rate of transfused patients of the blood type 0 
(81 percent for transfused patients, compared to 38 percent for untrans-
fused patients), as compared to A, Band AB transfused patients {55 
percent for transfused patients compared to 39 percent for untransfused 
patients). Our study, which consists of too small a population to 
yield statistically-significant results, strongly indicates superior 
reduction in acute rejection for transfused 0 patients (zero out of 
eleven, or zero percent for transfused 0 patients compared to one out 
of two, or fifty percent for nontransfused 0 patients), as compared to 
A, B-and AB transfused patients (six out of fourteen, or 43 percent for 
transfused A, Band AB patients, compared to five of twelve for non-
transfused A, B and AB patients). These results suggest the blood 
group, or a factor closely related to it, determines the fate of the 
grafted kidney (201). Opelz and his coworkers (202) have suggested 
that the harmful effects of cytotoxic antibodies may be restricted to 
certain recipient blood groups. However, since the 0 blood group is 
a homogenous group in that it only received 0 blood transfusions, whereas 
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A, Band AB patients are nonhomogenous groups, further studies need to 
be carried out before conclusions about the effect that a patient•s 
blood type has on his or her chances of having a successful transplant 
can be drawn. To illustrate this point, Opelz and coworkers (202) 
recently demonstrated that the blood group of the recipient (0 or non-
0) presented no advantage in the twelve-month graft survival of trans-
fused patients. 
While there has been a good deal of work done on the various 
effects of blood transfusions on graft survival, little is known about 
the mechanism(s) involved in the graft-protective effects. Of the 
several mechanisms suggested, two major categories can be constructed. 
The first category would consist of a 11 Selection mechanism, 11 in which 
either a patient or donor would be secluded from the transplantation 
procedure. Some patients who receive transfusions respond by making 
antibodies that react with cells from potential donors. Thus, trans-
fusion might constitute a method of identifying individuals who produce 
extremely strong antibody reactions, and might consequently be high-
risk graft recipients, eliminating them from the transplantation pool. 
On the other hand, if the antibody response is weak, transfusion would 
allow for the selection of more compatible donors. It is of interest 
to note that HLA-A and B antibodies have been ascribed both beneficial 
effects (202), no effect (133, 149), or even deleterious effects (135) 
on first cadaveric-kidney grafts provided a negative crossmatch. Recent 
studies by the Southeastern Organ Procurement Foundation (SEOPF) and 
the NIAID, have shown that while there is a small, but significant im-
provement in one-year kidney survival roles in cases where there is a 
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it appears from the SEOPF study that transfusion makes a larger con-
tribution to one-year-kidney graft survival than does a well-matched 
HLA-A and B donor-recipient pair (198). According to G. Melville 
Williams, who presented some of the SEOPF data at the 7th International 
Convocation on Immunology, the effects of transfusion and anti-
lymphocyte serum (see next section) appear to occur within the first 
six months after transplantation, a time when about 50 percent of the 
graft rejections occur. The positive effects of HLA-A and B matching 
do not become apparent until twelve to eighteen months posttransplant, 
when a good match appears to have a stabilizing effect on the survival 
of kidneys that made it through the earlier, more hazardous time (198). 
Before discussing the second mechanism of.graft improvement, it should 
be pointed out that recent studies suggest that the matching of another 
HLA antigen, D-related (DR), appears to be more important for kidney-
graft survival than either HLA-A or B matching; however, additional 
studies are required to verify these early observations. 
The second mechanism which has been suggested, includes both 
specific and non-specific immunological mechanisms. Specific immune 
mechanisms include enhancement, i.e., process by which serum-blocking 
antibodies prolong graft survival, and tolerance, i.e., denotes a 
condition of unresponsiveness caused by the elimination or inactivation 
of responsive cell clones (T-cell orB-cell) and/or by suppressor T-cells. 
Although B-cell antibodies have been found in the sera of transfused 
patients prior to and following transplantation, it is unlikely that 
antibodies directed against DR antigens for which donor and host are 
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disparate, could be solely responsible for graft impr~vement after 
just a single transfusion (144, 203). In addition, recent data indi-
cates that anti-HLA-DR antibodies can induce hyperacute or accelerated 
rejection (204). For the same reason, (efficiency of a single trans-
fusion), prolonged graft survival is unlikely to be due to the presence 
of antiidiotypic antibodies, i.e., antibodies directed against antigenic 
determinant unique to the antigen-binding region of an immunoglobulin. 
However, the possibility exists that other 8-cell antibodies induced 
by blood transfusions, e.g., cold cytotoxins, might be responsible for 
prolongation of graft survival (205). 
Another possible mechanism is that giving transfusions pre-
transplant and during transplants results in a state of unresponsiveness 
or tolerance, which decreases the chances.of recipient rejection, and, 
therefore, prolonged graft survival. Five possible mechanisms of 
tolerance induction are depicted in Figure 9 (206). Tolerance is an 
antigen-specific process. Since transfusion is not-donor specific, 
it is unlikely that tolerance is responsible for the improved graft 
survival. Nevertheless, reduced cell-mediated lympholysis activity is 
seen in particularly successful renal allograft patients, suggesting 
that for these individuals some form of tolerance exists (207). Mixed 
lymphocyte culture experiments (see Section IA-4) have shown that 
suppressor cells can be activated in vitro by specific (antigen) and 
nonspecific (mitogen) means. Thus, it is possible that transfusion 
induces a state of tolerance in the recipient by nonspecifically activa-
ting suppressor cells. 
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Figure 9. Possible mechanisms of tolerance induction. 
Schematically represented is the immune response and 
five possible mechanisms of induction of tolerance. 
These include: 1) clonal elimination of the potentially 
responding T or B cell population; 2) activation of 
suppressor T cells specific for the tolerogen; 3) 
presence of blocking antibody that prevents further 
antigen stimulation; 4) production of an antibody to 
idiotypic (antireceptor) that blocks further 
activation of antigen specific T or B cells that bear 
that receptor; and 5) catabolism of the antigen that 
bypasses normal immune recognition or induction 
processes. 
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MECHANIS.\fS OF TOLERAI\'CE 
Immune Tolerance 
I Clonal Elimination 
II Suppressor Cells 
IV Anti - ldiotype (Network) 
A93 + 
V Antigen Catabolism 
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As for nonspecific mechanisms, Keown and Descamps (197) have 
suggested two mechanisms whereby erythrocytes can nonspecifically 
depress the immune system of the transfused patient, thereby prolonging 
graft survival. The first mechanism would involve phagocytosis and 
lysis of red blood cells impeding the coincident or subsequent pro-
cessing of antigen by mononuclear phagocytes, thus impairing antigen 
presentation and lymphocyte activation. Such inhibition could be 
attributed to a transient blockade of phagocytosis, interference with 
mechanisms intrinsic to antigen degradation (208), or to the more 
fundamental inhibition of cellular metabolism via the regulation of 
cation transport by ferric ions (209). The observation that Fe(+3) 
alone, at concentrations equivalent to that present in hemoglobin, 
exerts an equally-powerful depressive effect on antigen stimulation 
(210), argues in favor of this mechanism. The other mechanism, in-
volves the production of an immunoregulatory messenger by mononuclear 
phagocytes which have been induced by the endocytosis of red blood cells. 
The messenger could be prostaglandin-related. Prostaglandins are 
rapidly produced in vitro after endocytosis of red blood cells (211); 
and their derivatives have been shown to inhibit the generation of 
cell-mediated cytotoxicity in vivo, and prolong allograft survival 
(212, 213). Solheim and coworkers (142) argue against a strong non-
specific mechanism, based on observation that neither graft survival nor 
first rejection frequency is affected by blood transfusions in HLA-
identical transplants. However, significant improvement in graft func-
tion and survival in HLA-identical transplants might not be expected 
since this combination of transplants manifests less rejection. Thus, 
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it appears that a nonspecific mechanism for allograf~ prolongation is 
plausible; however, additional studies with pure erythrocytes, i.e., 
devoid of HLA-antigen containing reticulocytes, are needed to resolve 
the mechanism. In addition, the fact that suppressor cells have been 
shown to depress cell-mediated responses (16, 20, 57-63), and can be 
induced by nonspecific means (22), suggests that suppressor cells may 
play an important role in renal allograft prolongation. 
IVB-3. Role for Antithymocyte Globulin in 
Renal Allograft Survival 
Since Starzl and his coworkers (153) first used antilympho-
cyte globulin (ALG) in clinical renal transplants, several studies 
(154-162) have been carried out to determine what effects ALG or anti-
thymocyte globulin (ATG) have on graft function and survival, when used 
in place of, or more commonly, as an adjunct to conventional immuno-
suppressive therapy. While some of the studies show improvement in 
graft function and survival (153, 158, 163), the majority of studies 
have been unable to demonstrate any significant improvement in graft 
function and/or survival with ALGor ATG (156, 159, 160-162). In 
addition, ALG and ATG have been shown to cause severe immunological 
reactions (214-217), necessitating their premature discontinuation. 
Our study indicates that fewer patients treated with ATG ex-
perienced acute rejection (four out of nineteen patients, or 21 per-
cent) than patients not receiving ATG (ten out of thirty-three, or 
30 percent). In addition, none of the patients who were treated with 
ATG, and experienced an acute rejection episode, suffered loss of their 
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kidney graft; whereas, two of the ten patients who had a rejection 
episode, and did not receive ATG, lost their graft. While our results 
on graft rejection are not statistically significant ( x2 = 0.52) 
for one degree of freedom), they do suggest that the treatment of 
patients with ATG decreases their chances for graft rejection. Similar 
findings have been made by Taylor et al. (158). In their study, they 
found that patients treated with ALG (20 mg/kg/day) intravenously, in 
addition to their standard immunosuppressive therapy, experienced less 
than half the number of acute rejection episodes, and had better-
accumulated graft survival. Furthermore, they found that patients 
treated with ATG had significantly better renal function (serum creati-
nine and creatinine clearance) values at both one-month and two-months 
posttransplant, than non-ATG-treated patients; however, the renal 
function values at one-year posttransplant were the same for the two 
groups. Our results (Table 19) show that nonrejecting-transplant 
patients (Groups I and II) have almost identical renal function values 
whether or not they received ATG. However, these two groups of patients 
have mean posttransplant times of fifteen months and 17.8 months, res-
pectively; therefore, our results agree with those of Taylor et al. 
(158). Moreover, examination of the two rejection groups (Group III 
and IV), which have mean posttransplant times of 2.5 months and 1.5 
months, respectively, demonstrates that ATG had a slight, but positive 
effect on renal allograft function. 
The results in Table 20 demonstrate that ATG is without influence 
on the total lymphocyte number, T-cell number, and B-cell number of non-
rejection patients (Groups I and II). However, ATG treatment does appear 
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to have a positive effect on the total lymphocyte number, and espe-
cially on the T-cell number of rejection patients (Group III). Similar 
results had been earlier reported by Birkeland.et ~ (218). 
A possible explanation for the conflictive nature of the 
benefits of ATG treatment might be that the previous studies have used 
ATG only as an adjunct to conventional steroid therapy. In order to 
accurately access the potential of ATG, experiments must be carried out 
in which ATG is used in place of high-dose steroid therapy. Such a 
study has been recently carried out by Shield et al. (163). Patients 
were initially treated with azathioprine and prednisone. With the onset 
of acute rejection, patients were randomly assigned to additional 
treatment with either ATG or high-dose steriods. Eight of the ten 
patients treated with ATG had prompted reversal of acute rejection. 
All ten of the patients treated with high-dose steroids had prompted 
reversal of acute rejection; however, four of the patients required 
irradiation of the graft and actinomycin treatment. Furthermore, five 
of the patients required treatment for second and third rejection 
episodes. A fourteen-month followup found nine of the ten patients 
treated with ATG having functional allografts, with eight of the nine 
showing normal renal function. On the other hand, nine of ten patients 
treated with high-dose steroids had function grafts, but renal function 
remained impaired in three. Therefore, it appears that the major ad-
vantage of using ATG is that it decreases the number of second rejection 
episodes, and also allows for the decreased use of high-dose steroids 
which have been implicated in fatal diverticulitis, as well as several 
other disorders. 
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Finally, while ATG appears to be effective in reducing the 
number of acute rejection episodes, its use on several occasions has had 
to be curtailed due to the manifestation of severe immunological reac-
tions. In a recent report, Abdou·et al. (219) showed that deaggregated 
ATG (dATG) prepared by centrifugation at 40,000 x g for one hour and 
filtered through a 0.45 urn millipore filter, induced a state of toler-
ance in patients without the severe immunological complications seen 
when aggregated ATG is used. The tolerance induced by dATG appears to 
be mediated by antigen-specific suppressor T-cells which carry receptors 
for the horse serum, and lasts for a few weeks after dATG administration. 
Therefore, it may be possible to treat acute rejection with dATG, thus 
avoiding the negative side effects of ATG. 
CHAPTER V 
CONCLUSIONS 
1. Renal transplant patients who are within their first year of 
transplantation display low suppressor lymphocyte activity. 
2. Renal transplant patients who have retained their grafts for 
a period of time greater than one year display an average 
suppressor lymphocyte activity which approaches the value 
of healthy individuals. 
3. The suppressor lymphocyte assay used in our research is neither 
precise or specific enough to predict a rejection episode. 
4. Acute rejection episodes take place in an environment of 
reduced T and B lymphocyte numbers. 
5. Statistical analysis of the effects of splenectomy, pre-
transplant transfusion, and antithymocyte globulin (ATG) 
administration on graft rejection show that only splenectomy 
has a statistically significant effect on decreasing the 
likelihood of a rejection episode. However, it should be 
pointed out that the Splenectomized-Non-Rejection Group 
(Group II, Table 11) contains a greater number of individuals 
who have received a donor graft from a living-related 
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individual, than either the Transfused-Non-Rejection Group or 
the ATG Administered-Non-Rejection Group (Table 11). Since 
transplantation with a living-related graft has been shown to 
have a greater survival rate {90% graft survival with living-
related grafts, as compared to a survival rate of 50% when the 
donor organ comes from a cadaver), the decreased rate of 
rejection episodes might be influenced to a greater degree by 
the source of the graft than the therapeutic effect of the 
splenectomy. 
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